Unnamed: 0,title,date,stock,sentiment
693141.0,10 Biggest Price Target Changes For Monday,2020-06-01 08:21:00-04:00,JAZZ,neutral
693142.0,"SVB Leerink Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $169",2020-06-01 06:55:00-04:00,JAZZ,neutral
693143.0,"Notable Insider Buys: Avis, Dynavax And Formula One",2020-05-30 17:12:00-04:00,JAZZ,neutral
693144.0,Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings,2020-05-14 09:55:00-04:00,JAZZ,positive
693145.0,Bionical Emas And Jazz Pharmaceuticals Enter Into An Agreement For Expanded Access To Lurbinectedin In Relapsed Small Cell Lung Cancer In The United States,2020-05-11 08:35:00-04:00,JAZZ,positive
693146.0,"SunTrust Robinson Humphrey Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target of $153",2020-05-06 12:02:00-04:00,JAZZ,negative
693147.0,"BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $193",2020-05-06 11:28:00-04:00,JAZZ,negative
693148.0,"SVB Leerink Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $160",2020-05-06 10:53:00-04:00,JAZZ,negative
693149.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,JAZZ,positive
693150.0,Jazz Pharmaceuticals shares are trading lower after the company reported Q1 EPS is down year over year and worse-than-expected Q1 sales results. The company also cut FY20 sales guidance.,2020-05-05 16:39:00-04:00,JAZZ,negative
693151.0,Jazz Pharmaceuticals Cuts FY20 Sales Guidance From $2.32B-$2.4B To $2.12B-$2.26B Vs. $2.48B Est.,2020-05-05 16:24:00-04:00,JAZZ,negative
693152.0,"Jazz Pharmaceuticals Q1 EPS $(2.820) Down From $1.470 YoY, Sales $535.000M Miss $543.590M Estimate",2020-05-05 16:22:00-04:00,JAZZ,negative
693153.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,JAZZ,positive
693154.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,JAZZ,neutral
693155.0,"Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $162",2020-04-30 11:38:00-04:00,JAZZ,negative
693156.0,"Oppenheimer Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $141",2020-04-30 09:26:00-04:00,JAZZ,negative
693157.0,Jazz Pharmaceuticals Stops Enrollment For Its Phase 3 Study Evaluating Defibrotide For The Prevention Of Veno-Occlusive Disease,2020-04-29 16:17:00-04:00,JAZZ,negative
693158.0,Jazz Pharmaceuticals Says Porton Biopharma Limited Entered Into New Agreement With New Partner to Commercialize & Distribute Erwinaze,2020-04-16 06:54:00-04:00,JAZZ,positive
693159.0,"Jefferies Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target to $149",2020-04-06 10:12:00-04:00,JAZZ,neutral
693160.0,"Morgan Stanley Maintains Equal-Weight on Jazz Pharmaceuticals, Lowers Price Target to $109",2020-04-02 09:19:00-04:00,JAZZ,negative
693161.0,"Jazz Pharmaceuticals Says It Has Over $1 Billion In Cash and In Invesments, The Company Sees A Limited Financial Impact Due To Coronavirus",2020-03-31 16:03:00-04:00,JAZZ,negative
693162.0,"7 Stocks To Watch For March 26, 2020",2020-03-26 05:15:00-04:00,JAZZ,neutral
693163.0,6 Stocks Moving In Wednesday's After-Hours Session,2020-03-25 16:52:00-04:00,JAZZ,neutral
693164.0,Jazz Pharmaceuticals shares are trading higher after the company announced FDA acceptance of its New Drug Application for JZP-258.,2020-03-25 16:11:00-04:00,JAZZ,positive
693165.0,Jazz Pharmaceuticals Announces FDA Acceptance Of New Drug Application For JZP-258 For Cataplexy And Excessive Daytime Sleepiness Associated With Narcolepsy,2020-03-25 16:06:00-04:00,JAZZ,positive
693166.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,JAZZ,negative
693167.0,"B of A Securities Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $163",2020-03-23 08:48:00-04:00,JAZZ,positive
693168.0,"Zoetis Shares Up 5% After Hours; SunTrust Earlier Discussed Expectations Drugmakers Won't See Near-Term Debt Crisis, Sees Co., Jazz Pharma As Strongest Positioned In Terms Of Debt, Leverage",2020-03-18 16:16:00-04:00,JAZZ,positive
693169.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,JAZZ,positive
693170.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,JAZZ,negative
693171.0,"Benzinga's Top Upgrades, Downgrades For March 12, 2020",2020-03-12 09:57:00-04:00,JAZZ,positive
693172.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,JAZZ,negative
693173.0,"Bernstein Upgrades Jazz Pharmaceuticals to Outperform, Lowers Price Target to $166",2020-03-12 06:33:00-04:00,JAZZ,negative
693174.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,JAZZ,positive
693175.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,JAZZ,negative
693176.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,JAZZ,negative
693177.0,"SunTrust Robinson Humphrey Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $166",2020-02-27 11:46:00-05:00,JAZZ,negative
693178.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,JAZZ,positive
693179.0,Stocks That Hit 52-Week Lows On Wednesday,2020-02-26 11:14:00-05:00,JAZZ,negative
693180.0,"BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $205",2020-02-26 09:15:00-05:00,JAZZ,negative
693181.0,"JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $183",2020-02-26 07:53:00-05:00,JAZZ,neutral
693182.0,Jazz Pharmaceuticals Sees FY20 Sales $2.320B-$2.4B Vs $2.36B Estimates,2020-02-25 16:22:00-05:00,JAZZ,neutral
693183.0,"Jazz Pharmaceuticals Q4 EPS $4.42 Beats $4.12 Estimate, Sales $581.74M Beat $561.69M Estimate",2020-02-25 16:20:00-05:00,JAZZ,neutral
693184.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,JAZZ,negative
693185.0,"Earnings Scheduled For February 25, 2020",2020-02-25 04:26:00-05:00,JAZZ,neutral
693186.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,JAZZ,neutral
693187.0,PharmaMar And Jazz Pharmaceuticals On Monday Announced FDA Acceptance And Priority Review Of New Drug Application For Lurbinectedin In Relapsed Small Cell Lung Cancer,2020-02-18 09:12:00-05:00,JAZZ,negative
693188.0,Jazz Pharma Shares Volatile As Hearing FDA Says Reports Of Serious Risk Of Suicidal Behavior In Patients Taking Co.'s Sunosi,2020-02-05 09:41:00-05:00,JAZZ,negative
693189.0,"Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $189",2020-01-22 09:07:00-05:00,JAZZ,negative
693190.0,Jazz Pharmaceuticals Submits New Drug Application For JZP-258 For Cataplexy And Excessive Daytime Sleepiness Associated With Narcolepsy,2020-01-22 08:01:00-05:00,JAZZ,neutral
693191.0,PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period,2020-01-22 05:18:00-05:00,JAZZ,positive
693192.0,Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea,2020-01-20 18:12:00-05:00,JAZZ,neutral
693193.0,Jazz Pharmaceuticals Announces First Patient Enrolled In Pivotal Phase 2/3 Study Evaluating JZP-458 For Treatment Of Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma,2019-12-30 08:02:00-05:00,JAZZ,neutral
693194.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,JAZZ,negative
693195.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,JAZZ,negative
693196.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,JAZZ,neutral
693197.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,JAZZ,neutral
693198.0,"PharmaMar, Jazz Pharma Report Exclusive License Deal for Lurbinectedin In US",2019-12-19 08:07:00-05:00,JAZZ,positive
693199.0,Pfenex Earns $15M Development Milestone Under Its Development And License Agreement With Jazz Pharmaceuticals,2019-12-18 08:10:00-05:00,JAZZ,positive
693200.0,"Wells Fargo Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $186",2019-12-03 08:27:00-05:00,JAZZ,positive
693201.0,10 Biggest Price Target Changes For Monday,2019-12-02 08:52:00-05:00,JAZZ,neutral
693202.0,"Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $200",2019-12-02 07:04:00-05:00,JAZZ,negative
693203.0,EU's CHMP Gives Positive Opinion For Jazz Pharma's Sunosi For Treatment Of Excessive Daytime Sleepiness,2019-11-15 06:35:00-05:00,JAZZ,positive
693204.0,"Jazz Pharmaceuticals Q3 Adj. EPS $4.1 Beats $3.59 Estimate, Sales $537.702M Beat $525.16M Estimate",2019-11-05 16:12:00-05:00,JAZZ,neutral
693205.0,"Earnings Scheduled For November 5, 2019",2019-11-05 04:14:00-05:00,JAZZ,neutral
693206.0,"Bernstein Earlier Reinstated Market Perform on Jazz Pharmaceuticals, Announced $150 Price Target",2019-10-14 11:49:00-04:00,JAZZ,neutral
693207.0,Jazz Pharmaceuticals Announces First Patient Enrolled In Phase 2 Clinical Trial Evaluating Defibrotide For The Prevention Of CAR-T Associated Neurotoxicity,2019-10-10 16:22:00-04:00,JAZZ,neutral
693208.0,"5 Stocks To Watch For October 8, 2019",2019-10-08 05:39:00-04:00,JAZZ,neutral
693209.0,Jazz Pharmaceuticals CFO Matthew Young To Resign,2019-10-07 17:11:00-04:00,JAZZ,negative
693210.0,Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar,2019-10-03 15:49:00-04:00,JAZZ,positive
693211.0,"The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J",2019-09-26 07:54:00-04:00,JAZZ,positive
693212.0,"The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication",2019-09-06 07:27:00-04:00,JAZZ,neutral
693213.0,"Benzinga's Top Upgrades, Downgrades For August 21, 2019",2019-08-21 09:50:00-04:00,JAZZ,positive
693214.0,10 Biggest Price Target Changes For Wednesday,2019-08-21 09:16:00-04:00,JAZZ,neutral
693215.0,"Piper Jaffray Downgrades Jazz Pharmaceuticals to Neutral, Lowers Price Target to $142",2019-08-21 06:51:00-04:00,JAZZ,negative
693216.0,"The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results",2019-08-13 07:25:00-04:00,JAZZ,neutral
693217.0,Jazz Pharmaceuticals Acquires Cavion; Cavion Shareholders To Receive Upfront Payment Of $52.5M And Up To $260M In Milestone Payments,2019-08-12 16:03:00-04:00,JAZZ,neutral
693218.0,"Jazz Pharma Raises FY19 Sales Guidance From $2.05B-$2.13B To $2.07B-$2.15B vs $2.09B Estimate, Reaffirms Adj. EPS Guidance $14.30-$15 vs $14.81 Est.",2019-08-06 16:51:00-04:00,JAZZ,neutral
693219.0,"Jazz Pharmaceuticals Q2 EPS $4.05 Beats $3.58 Estimate, Sales $534.133M Beat $508.83M Estimate",2019-08-06 16:49:00-04:00,JAZZ,neutral
693220.0,"Jazz Pharma Reports Advancement Of Recombinant Crisantaspase Development Program; Phase 1 Study Complete, Phase 2/3 Study Expected To Begin Later In 2019",2019-08-06 16:02:00-04:00,JAZZ,neutral
693221.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,JAZZ,positive
693222.0,"Earnings Scheduled For August 6, 2019",2019-08-06 04:00:00-04:00,JAZZ,neutral
693223.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,JAZZ,neutral
693224.0,30 Stocks Moving In Monday's Pre-Market Session,2019-07-15 08:07:00-04:00,JAZZ,neutral
693225.0,"The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV",2019-07-10 07:17:00-04:00,JAZZ,positive
693226.0,"Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma for $3.5M Upfront, Up to $203M in Milestones",2019-07-10 04:24:00-04:00,JAZZ,negative
693227.0,8 Biggest Price Target Changes For Wednesday,2019-07-03 10:29:00-04:00,JAZZ,neutral
693228.0,28 Stocks Moving In Monday's Pre-Market Session,2019-06-17 08:06:00-04:00,JAZZ,neutral
693229.0,Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi,2019-06-17 08:01:00-04:00,JAZZ,neutral
693230.0,"Barclays Initiates Coverage On Jazz Pharmaceuticals with Overweight Rating, Announces $164 Price Target",2019-06-11 07:14:00-04:00,JAZZ,negative
693231.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,JAZZ,positive
693232.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,JAZZ,neutral
693233.0,Jazz Pharmaceuticals Announces That 14 Abstracts Sponsored By Co. And One Abstract From An Investigator-Sponsored Trial Will Be Presented At The 33Rd Annual Meeting Of The Associated Professional Sleep Societies June 8-12,2019-05-09 09:37:00-04:00,JAZZ,neutral
693234.0,Jazz Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS and sales results and reaffirmed FY19 guidance. BMO Capital maintained an Outperform rating on the stock.,2019-05-08 10:16:00-04:00,JAZZ,positive
693235.0,"Mizuho Maintains Neutral on Jazz Pharmaceuticals plc - Ordinary Shares, Raises Price Target to $148",2019-05-08 09:11:00-04:00,JAZZ,positive
693236.0,"BMO Capital Maintains Outperform on Jazz Pharmaceuticals plc - Ordinary Shares, Raises Price Target to $208",2019-05-08 08:31:00-04:00,JAZZ,positive
693237.0,"Jazz Pharma Reaffirms FY19 Guidance: Adj. EPS $14.30-$15 vs $14.60 Estimate, Sales $2.05B-$2.13B vs $2.07B Est.",2019-05-07 16:20:00-04:00,JAZZ,neutral
693238.0,"Jazz Pharmaceuticals Q1 Adj. EPS $3.67 Beats $3.16 Estimate, Sales $508.186M Beat $465.95M Estimate",2019-05-07 16:20:00-04:00,JAZZ,neutral
693239.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,JAZZ,neutral
693240.0,"Earnings Scheduled For May 7, 2019",2019-05-07 05:03:00-04:00,JAZZ,neutral
693241.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,JAZZ,neutral
693242.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,JAZZ,negative
693243.0,Betaville Article Discusses Trader Speculation Of Jazz Pharmaceuticals Interest In Acquiring TG Therapeutics,2019-04-17 15:07:00-04:00,JAZZ,positive
693244.0,'Three drug makers settle allegations of using charities to pay kickbacks to Medicare patients' -Stat News,2019-04-04 12:08:00-04:00,JAZZ,positive
693245.0,UPDATE: Jazz Pharma To Pay $57M Plus Interest At 2.75%,2019-04-04 10:32:00-04:00,JAZZ,positive
693246.0,"Jazz Pharma 8-K Shows Entered Civil Settlement Deal With US Dept. Of Justice, Office Of Inspector General Of Dept. Of Health And Human Services",2019-04-04 10:32:00-04:00,JAZZ,positive
693247.0,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",2019-03-27 07:52:00-04:00,JAZZ,positive
693248.0,UPDATE: Jazz Says 'Two patients experienced serious adverse events (SAEs) that were considered by the investigator to be treatment related.',2019-03-26 16:17:00-04:00,JAZZ,negative
693249.0,"UPDATE: Jazz Pharma Says 'treatment-emergent adverse events that occurred in ≥5% of patients who received JZP-258 were headache, nausea, dizziness, cataplexy, nasopharyngitis, decreased appetite, influenza, diarrhea and vomiting'",2019-03-26 16:17:00-04:00,JAZZ,negative
693250.0,"Jazz Pharma Reports Top-Line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness: Achieved Primary, Key Secondardy Endpoints",2019-03-26 16:15:00-04:00,JAZZ,neutral
693251.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-23 12:20:00-04:00,JAZZ,neutral
693252.0,"The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering",2019-03-21 07:51:00-04:00,JAZZ,negative
693253.0,31 Stocks Moving In Thursday's Pre-Market Session,2019-03-21 07:50:00-04:00,JAZZ,neutral
693254.0,"The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company",2019-03-20 07:46:00-04:00,JAZZ,negative
693255.0,SunTrust Robinson Humphrey Initiates Coverage On Jazz Pharmaceuticals with Buy Rating,2019-03-20 07:16:00-04:00,JAZZ,neutral
693256.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-03-16 08:35:00-04:00,JAZZ,neutral
693257.0,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",2019-03-12 07:47:00-04:00,JAZZ,positive
693258.0,"Morgan Stanley Maintains Equal-Weight on Jazz Pharmaceuticals, Lowers Price Target to $135",2019-03-08 08:49:00-05:00,JAZZ,negative
693259.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2019-03-04 11:50:00-05:00,JAZZ,neutral
693260.0,84 Biggest Movers From Yesterday,2019-02-28 05:10:00-05:00,JAZZ,neutral
693261.0,72 Stocks Moving In Wednesday's Mid-Day Session,2019-02-27 12:20:00-05:00,JAZZ,neutral
693262.0,Jazz Pharmaceuticals shares are trading higher after the company beat Q4 sales and EPS estimates; the company also provided FY19 sales guidance above analyst estimates.,2019-02-27 11:46:00-05:00,JAZZ,positive
693263.0,"BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $206",2019-02-27 09:12:00-05:00,JAZZ,neutral
693264.0,35 Stocks Moving In Wednesday's Pre-Market Session,2019-02-27 08:25:00-05:00,JAZZ,neutral
693265.0,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",2019-02-27 08:13:00-05:00,JAZZ,neutral
693266.0,6 Stocks Moving In Tuesday's After-Hours Session,2019-02-26 17:22:00-05:00,JAZZ,neutral
693267.0,Jazz Pharma Sees FY19 Sales $2.05B-$2.13B vs $2.03B Estimate,2019-02-26 16:11:00-05:00,JAZZ,neutral
693268.0,"Jazz Pharmaceuticals Q4 Adj. EPS $3.64 Beats $3.02 Estimate, Sales $476.457M Beat $459.72M Estimate",2019-02-26 16:11:00-05:00,JAZZ,neutral
693269.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,JAZZ,positive
693270.0,"Earnings Scheduled For February 26, 2019",2019-02-26 04:02:00-05:00,JAZZ,neutral
693271.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,JAZZ,neutral
693272.0,Jazz Pharmaceuticals Announces Cancer Treatment Collaboration Collaboration With Codiak BioSciences; Co. Will Pay Codiak $56M Upfront And Up To $200M In Milestones Per Target,2019-01-03 16:09:00-05:00,JAZZ,negative
693273.0,Jazz Pharmaceuticals Receives New PDUFA Goal Date Of March 20 For Solriamfetol In Excessive Daytime Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea,2018-12-21 07:03:00-05:00,JAZZ,neutral
693274.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,JAZZ,positive
693275.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-16 14:18:00-05:00,JAZZ,neutral
693276.0,"Benzinga's Top Upgrades, Downgrades For December 12, 2018",2018-12-12 09:28:00-05:00,JAZZ,positive
693277.0,"Oppenheimer Initiates Coverage On Jazz Pharmaceuticals with Outperform Rating, Announces $180 Price Target",2018-12-12 08:21:00-05:00,JAZZ,neutral
693278.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,JAZZ,neutral
693279.0,Jazz Pharma Adds $400M To Buyback,2018-12-10 16:10:00-05:00,JAZZ,neutral
693280.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2018-11-30 13:09:00-05:00,JAZZ,neutral
693281.0,Jazz Pharmaceuticals Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating JZP-258 For The Treatment Of Idiopathic Hypersomnia,2018-11-29 08:07:00-05:00,JAZZ,neutral
693282.0,"B. Riley FBR Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $190",2018-11-08 11:29:00-05:00,JAZZ,negative
693283.0,88 Biggest Movers From Yesterday,2018-11-08 04:54:00-05:00,JAZZ,neutral
693284.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,JAZZ,negative
693285.0,"Jazz Pharmaceuticals plc Q3 EPS $3.58 Beats $3.32 Estimate, Sales $469.373M Miss $482.21M Estimate",2018-11-06 16:20:00-05:00,JAZZ,negative
693286.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,JAZZ,positive
693287.0,"Earnings Scheduled For November 6, 2018",2018-11-06 05:31:00-05:00,JAZZ,neutral
693288.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,JAZZ,neutral
693289.0,Jazz Pharmaceuticals Announces FDA Approval of Xyrem for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients,2018-10-29 08:00:00-04:00,JAZZ,positive
693290.0,"Benzinga's Week Ahead: Can Tech Earnings Restore The Rally? Amazon, Google To Report",2018-10-22 12:49:00-04:00,JAZZ,positive
693291.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,JAZZ,neutral
693292.0,UPDATE: Jazz Is Entitled To Receive A Meaningful Royalty On Net Sales Of Amneal Product 'as well as payment for the supply of the Amneal AG Product and reimbursement for a portion of the services costs associated with distribution...',2018-10-11 16:42:00-04:00,JAZZ,positive
693293.0,"UPDATE: Jazz Pharma Settlement Dictates Amneal Will Have Non-Exclusive Rights To Sell Limited Volume Of An Authorized Generic Version Of Xyrem From Jul. 1, 2023 To Dec. 31, 2025 Or Earlier Under Certain Circumstances",2018-10-11 16:41:00-04:00,JAZZ,positive
693294.0,Jazz Pharma 8-K Shows Co. Settled Ongoing Patent Litigation Against Amneal Pharma Related To Amneal's ANDA Seeking To Market Generic Xyrem,2018-10-11 16:40:00-04:00,JAZZ,negative
693295.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2018-09-26 16:41:00-04:00,JAZZ,neutral
693296.0,REMINDER: Jazz Pharma Holding Webcast Today To Discuss Vyxeos Launch,2018-09-18 06:40:00-04:00,JAZZ,neutral
693297.0,"The Week Ahead: Alibaba Investor Day, FedEx Earnings, Eventbrite IPO",2018-09-17 14:46:00-04:00,JAZZ,neutral
693298.0,Jazz Pharmaceuticals Earlier Announced That The European Commission Has Approved Vyxeos For Myeloid Leukaemia,2018-08-27 08:39:00-04:00,JAZZ,positive
693299.0,10 Biggest Price Target Changes For Wednesday,2018-08-08 09:44:00-04:00,JAZZ,neutral
693300.0,"BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $206",2018-08-08 08:37:00-04:00,JAZZ,neutral
693301.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,JAZZ,positive
693302.0,40 Stocks Moving In Wednesday's Pre-Market Session,2018-08-08 08:08:00-04:00,JAZZ,neutral
693303.0,"Stifel Nicolaus Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $205",2018-08-08 07:19:00-04:00,JAZZ,neutral
693304.0,8 Stocks Moving In Tuesday's After-Hours Session,2018-08-07 16:52:00-04:00,JAZZ,neutral
693305.0,"Jazz Reaffirms FY18 Guidance: Adj. EPS $12.75-$13.25 vs $13.09 Estimate, Sales $1.88B-$1.93B vs $1.9B Est.",2018-08-07 16:16:00-04:00,JAZZ,neutral
693306.0,Jazz Raises FY18 Xyrem Sales Guidance To $1.35B-$1.38B,2018-08-07 16:15:00-04:00,JAZZ,neutral
693307.0,"Jazz Pharmaceuticals Q2 EPS $3.49 Beats $3.23 Estimate, Sales $500.479M Beat $469.62M Estimate",2018-08-07 16:15:00-04:00,JAZZ,neutral
693308.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,JAZZ,negative
693309.0,"Earnings Scheduled For August 7, 2018",2018-08-07 04:49:00-04:00,JAZZ,neutral
693310.0,Jazz Pharma Reports Collaboration With MD Anderson Cancer Center For Evaluation Of Potential Treatment Options For Hematologic Malignancies,2018-08-06 17:04:00-04:00,JAZZ,negative
693311.0,Jazz Pharma Reports Centers for Medicare and Medicaid Services Has Granted New Technology Add-On Payment To Vyxeos Liposome For Injection,2018-08-03 08:06:00-04:00,JAZZ,positive
693312.0,Journal Of Clinical Oncology publishes PivotalPhase 3 Date For Jazz Pharmaceuticals' Vyxeos (daunorubicin and cytarabine) Liposome For Injection,2018-07-19 16:46:00-04:00,JAZZ,neutral
693313.0,Evercore's Umer Raffat Says Today's Patent Ruling On Jazz Pharmaceuticals Is A Non-Issue And 'Not Particularly Relevant For Xyrem's Patent Estate',2018-07-13 10:15:00-04:00,JAZZ,neutral
693314.0,"Appeals Court Rejects Jazz Pharmaceutical's Bid To Revive Patents On Xyrem, Ruling Clears Way For Amneal Pharmaceutical's Luanch Of A Generic Version Of Xyrem",2018-07-13 09:50:00-04:00,JAZZ,negative
693315.0,Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target,2018-07-11 15:25:00-04:00,JAZZ,neutral
693316.0,"Benzinga's Top Upgrades, Downgrades For July 11, 2018",2018-07-11 09:05:00-04:00,JAZZ,positive
693317.0,"The Market In 5 Minutes: More Tariffs, App Store's Birthday, PPI Data And More",2018-07-11 09:01:00-04:00,JAZZ,neutral
693318.0,Morgan Stanley Downgrades Jazz Pharmaceuticals to Equal-Weight,2018-07-11 07:26:00-04:00,JAZZ,neutral
693319.0,"Citigroup Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $205",2018-07-10 07:26:00-04:00,JAZZ,neutral
693320.0,Jazz Pharma Enters Agreement With TerSera Therapetucis To Sell Its Rights To Prialt For $80M,2018-06-29 16:07:00-04:00,JAZZ,positive
693321.0,Jazz Pharma Reports Vyxeos Received Positive CHMP Opinion For Treatment Of Certain Types Of High-Risk Acute Myeloid Leukemia,2018-06-29 08:28:00-04:00,JAZZ,positive
693322.0,Jazz Pharma Announces FDA Acceptance of sNDA For Xyrem,2018-06-27 16:20:00-04:00,JAZZ,positive
693323.0,"B. Riley FBR Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $219",2018-06-26 08:14:00-04:00,JAZZ,neutral
693324.0,"Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street",2018-06-21 08:39:00-04:00,JAZZ,neutral
693325.0,"Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading",2018-06-20 08:36:00-04:00,JAZZ,negative
693326.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,JAZZ,positive
693327.0,Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea,2018-06-03 18:59:00-04:00,JAZZ,positive
693328.0,Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem in Pediatric Patients with Narcolepsy with Cataplexy,2018-06-03 18:58:00-04:00,JAZZ,positive
693329.0,"Bernstein Strategic Decisions 2018 Conference Concludes Today, Presenters Include: Colgate-Palmolive, KKR, JP MOrgan, Sabre, Alnylam, Jazz Pharmaceuticals, Valvoline, Lam Research, and Ally Financial",2018-06-01 08:46:00-04:00,JAZZ,positive
693330.0,"B. Riley FBR Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $211",2018-05-10 14:44:00-04:00,JAZZ,neutral
693331.0,"BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $201",2018-05-09 09:57:00-04:00,JAZZ,neutral
693332.0,Jazz Pharmaceuticals Agreed to Pay $57M to Resolve U.S. Investigation of Financial Support of Charities that offer Assistance to Medicare Patients,2018-05-09 04:10:00-04:00,JAZZ,positive
693333.0,"Jazz Pharma Sees FY18 Adj. EPS $12.75-$13.25 vs $13 Est., Sales $1.88B-$1.93B vs $1.89B Est.",2018-05-08 16:18:00-04:00,JAZZ,neutral
693334.0,"Jazz Pharmaceuticals Q1 Adj. EPS $2.98 Beats $2.77 Estimate, Sales $444.613M Beat $434.87M Estimate",2018-05-08 16:16:00-04:00,JAZZ,neutral
693335.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,JAZZ,neutral
693336.0,"Earnings Scheduled For May 8, 2018",2018-05-08 04:38:00-04:00,JAZZ,neutral
693337.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,JAZZ,neutral
693338.0,"Jazz Pharma Reports Submission Of sNDA For Xyrem To Treat Cataplexy, Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients",2018-05-01 08:37:00-04:00,JAZZ,positive
693339.0,Merger Monday Makes A Return,2018-04-30 15:24:00-04:00,JAZZ,neutral
693340.0,Spark Therapeutics Sells Priority Review Voucher for $110M To Jazz Pharmaceuticals,2018-04-30 07:30:00-04:00,JAZZ,positive
693341.0,"Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential",2018-03-19 09:37:00-04:00,JAZZ,positive
693342.0,"Benzinga's Top Upgrades, Downgrades For March 19, 2018",2018-03-19 09:11:00-04:00,JAZZ,positive
693343.0,Morgan Stanley Upgrades Jazz Pharmaceuticals to Overweight,2018-03-19 07:27:00-04:00,JAZZ,negative
693344.0,Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea,2018-03-02 08:30:00-05:00,JAZZ,positive
693345.0,Exclusive: Moleculin CEO Says Acute Myeloid Leukemia Candidate Could Be 'Remarkable',2018-03-01 13:38:00-05:00,JAZZ,positive
693346.0,"BMO Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $199.00",2018-02-28 11:33:00-05:00,JAZZ,neutral
693347.0,"Jazz Pharma Sees 2018 Adj. EPS $12.65-$13.25 vs. $13.07 Est., Sales $1.86B-$1.93B vs. $1.85B Est.",2018-02-27 16:09:00-05:00,JAZZ,neutral
693348.0,"Jazz Pharma Reports Q4 Adj. EPS $2.95 vs. $3.01 Est., Sales $436.4M vs. $441.3M Est.",2018-02-27 16:08:00-05:00,JAZZ,neutral
693349.0,Jazz Pharmaceuticals Q4 Earnings Outlook,2018-02-27 11:33:00-05:00,JAZZ,neutral
693350.0,"Earnings Scheduled For February 27, 2018",2018-02-27 04:01:00-05:00,JAZZ,neutral
693351.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-25 15:50:00-05:00,JAZZ,neutral
693352.0,Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease,2018-02-23 08:32:00-05:00,JAZZ,neutral
693353.0,National Comprehensive Cancer Network adds Jazz Pharmaceuticals' Vyxeos Liposome for Injection to Clinical Practice Guidelines in Oncology,2018-02-08 16:26:00-05:00,JAZZ,negative
693354.0,"JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma",2018-01-08 09:00:00-05:00,JAZZ,positive
693355.0,"Leerink Initiates Coverage On Jazz Pharmaceuticals with Outperform Rating, Announces $180.00 Price Target",2018-01-02 16:59:00-05:00,JAZZ,neutral
693356.0,"Cowen Out Positive On Jazz Pharmaceuticals, Says Accelerating Growth Is Ahead, Would Add Into This Soon To An 'Undervalued' Growth Story",2017-12-21 11:33:00-05:00,JAZZ,positive
693357.0,"Cantor Out Positive On Jazz Pharmaceutical, Says Next Leg Of Sleep Franchise Growth Is Established With NDA Filing of JZP-110; Firm Believes pitolisant Is Unlikely To Mount A Credible Competition To Xyrem or JZP-110",2017-12-21 10:20:00-05:00,JAZZ,positive
693358.0,Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol,2017-12-21 08:30:00-05:00,JAZZ,neutral
693359.0,Jazz Pharmaceuticals Names Daniel Swisher COO,2017-12-04 16:07:00-05:00,JAZZ,neutral
693360.0,"Benzinga's Top Upgrades, Downgrades For November 10, 2017",2017-11-10 09:30:00-05:00,JAZZ,positive
693361.0,"H.C. Wainwright Assumes Jazz Pharmaceuticals PLC at Neutral, Announces price target $150.00",2017-11-10 07:05:00-05:00,JAZZ,neutral
693362.0,13 Stocks Moving In Tuesday's After-Hours Session,2017-11-07 17:42:00-05:00,JAZZ,neutral
693363.0,"Jazz Pharma Sees FY17 Adj. EPS $10.70-$11.20 vs $10.89 Est., Sales $1.6B-$1.65B vs $1.64B Est.",2017-11-07 16:08:00-05:00,JAZZ,neutral
693364.0,"Jazz Pharma Reports Q3 Adj. EPS $3.22 vs $2.89 Est., Sales $411.855M vs $421M Est.",2017-11-07 16:08:00-05:00,JAZZ,neutral
693365.0,"Earnings Scheduled For November 7, 2017",2017-11-07 04:14:00-05:00,JAZZ,neutral
693366.0,Jazz Pharmaceuticals Submits Vyxeos Marketing Authorization Application to European Medicines Agency,2017-11-03 08:30:00-04:00,JAZZ,neutral
693367.0,"Benzinga's Top Upgrades, Downgrades For October 19, 2017",2017-10-19 09:08:00-04:00,JAZZ,positive
693368.0,"FBR Capital Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares with Buy Rating, Announces $206.00 Price Target",2017-10-19 08:24:00-04:00,JAZZ,positive
693369.0,"Goldman Sachs Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares with Neutral Rating, Announces $165.00 Price Target",2017-09-28 07:52:00-04:00,JAZZ,positive
693370.0,ImmunoGen Higher After Announcing Strategic Collaboration With Jazz Pharma,2017-08-29 14:00:00-04:00,JAZZ,neutral
693371.0,"Jazz Pharma and ImmunoGen Announces Agreement Granting Jazz Worldwide Rights to Opt into Development and Commercialization of 2 Early Stage Drugs, Jazz to Pay $75M Upfront",2017-08-29 06:31:00-04:00,JAZZ,positive
693372.0,"Benzinga's Top Upgrades, Downgrades For August 28, 2017",2017-08-28 09:24:00-04:00,JAZZ,positive
693373.0,"Benzinga's Top Upgrades, Downgrades For August 25, 2017",2017-08-25 09:11:00-04:00,JAZZ,positive
693374.0,"H.C. Wainwright Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares with Neutral Rating, Announces $144.00 Price Target",2017-08-25 07:13:00-04:00,JAZZ,positive
693375.0,"Jazz Pharmaceuticals Reports Q2 Adj. EPS $2.56 vs $2.75 Est., Sales $394.386M vs $410.82M Est.",2017-08-08 16:14:00-04:00,JAZZ,neutral
693376.0,"Earnings Scheduled For August 8, 2017",2017-08-08 04:35:00-04:00,JAZZ,neutral
693377.0,"Janney Out Positive On Jazz, Says Not Only Did They Get FDA Approval Of Vyxeos, But It Came With Broadest Possible Label; Raises Price Target From $180 to $192 And Reiterates Buy Rating",2017-08-03 12:07:00-04:00,JAZZ,positive
693378.0,FDA Approves Jazz Pharma's Vyxeos,2017-08-03 09:16:00-04:00,JAZZ,positive
693379.0,"Companies Holding Shareholder Meetings Today Include Apollo Investment, Booz Allen Hamilton, CorVel, Eagle Materials, Electronic Arts, Gladstone Investment, Jazz Pharmaceuticals, Michael Kors, Progressive, and Sprint",2017-08-03 08:55:00-04:00,JAZZ,neutral
693380.0,Jazz Pharma Enters License Agreement With XL-protein GmbH For Commercial Rights To PASylation Technology; Jazz Made $2M Upfront Payment,2017-07-26 17:09:00-04:00,JAZZ,positive
693381.0,Jazz Pharma Downgraded By Vetr,2017-06-20 12:38:00-04:00,JAZZ,neutral
693382.0,"Goldman Sachs Global Healthcare Confernce Begins Today, Presenters Include Mallinckrodt, Jazz Pharma, Community Health, and Juno Therapeutics",2017-06-13 06:35:00-04:00,JAZZ,neutral
693385.0,"Jazz Pharmaceuticals Annoucnes Data From Phase 3 JZP-110 Study, Shows Statistically Significant Effects Of Both Doses On Co-Primary Endpoints",2017-06-06 17:02:00-04:00,JAZZ,positive
693386.0,Jazz Pharmaceuticals Announces FDA Acceptance Of NDA For VYXEOS,2017-05-31 16:08:00-04:00,JAZZ,positive
693387.0,"Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected",2017-05-24 11:02:00-04:00,JAZZ,negative
693388.0,"UBS Global Health Care Conference Continues Today, Presenters Include: Celgene, Jazz Pharma, Depomed, Walgreens, And Zymeworks",2017-05-23 08:18:00-04:00,JAZZ,positive
693389.0,"Benzinga's Top Upgrades, Downgrades For May 15, 2017",2017-05-15 09:19:00-04:00,JAZZ,positive
693390.0,"RBC Capital Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares with Top Pick Rating, Announces $210.00 Price Target",2017-05-15 07:46:00-04:00,JAZZ,positive
693391.0,"Jazz Pharmaceuticals Sees FY17 Sales $1.625-$1.70B vs $1.67B Est., EPS $10.70-$11.30 vs $11.12 Est.",2017-05-09 16:07:00-04:00,JAZZ,neutral
693392.0,"Jazz Pharmaceuticals REports Q1 Adj. EPS $2.31 vs $2.34 Est., Sales $376M vs $377M Est.",2017-05-09 16:06:00-04:00,JAZZ,neutral
693393.0,"Earnings Scheduled For May 9, 2017",2017-05-09 04:32:00-04:00,JAZZ,neutral
693394.0,4 Medical Stocks That Could Be Big Winners Next Week,2017-05-05 16:26:00-04:00,JAZZ,positive
693395.0,Jazz Pharma Announces 'Positive' Phase 3 TONES Results,2017-04-26 17:02:00-04:00,JAZZ,neutral
693396.0,"Jazz Pharmaceuticals Announces Phase 2/3 Express Study Of Xyrem, Demonstrated Significant Differences In Primary And Secondary Efficacy Endpoints",2017-04-24 16:06:00-04:00,JAZZ,positive
693397.0,12 Biggest Mid-Day Gainers For Thursday,2017-04-06 14:03:00-04:00,JAZZ,neutral
693398.0,UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma,2017-04-06 13:45:00-04:00,JAZZ,positive
693399.0,7 Biggest Price Target Changes For Thursday,2017-04-06 10:21:00-04:00,JAZZ,neutral
693400.0,"Benzinga's Top Upgrades, Downgrades For April 6, 2017",2017-04-06 09:28:00-04:00,JAZZ,positive
693401.0,The Market In 5 Minutes,2017-04-06 09:22:00-04:00,JAZZ,neutral
693402.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-04-06 08:15:00-04:00,JAZZ,neutral
693403.0,"Mizuho Downgrades Jazz Pharmaceuticals To Neutral, Lowers Price Target To $150",2017-04-06 07:09:00-04:00,JAZZ,negative
693404.0,"Jazz Pharma Reaches Settlement With Hikma Pharma Related To Xyrem Patent Case, Grants Hikma Right To Sell Authorized Generic Version Commencing Jan 1, 2023",2017-04-05 16:31:00-04:00,JAZZ,positive
693405.0,Jazz Pharmaceuticals Completes Rolling Submission of NDA for Vyxeos,2017-04-03 09:07:00-04:00,JAZZ,neutral
693406.0,"Jazz Pharmaceuticals, Nippon Shinyaku Enter Into License Agreements for Development, Commercialization of Defitelio, Vyxeos in Japan; Financial Terms Not Disclosed",2017-03-30 03:38:00-04:00,JAZZ,positive
693407.0,'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market,2017-03-24 13:50:00-04:00,JAZZ,positive
693408.0,Jazz Pharma Shares Volatile Over Last Few Mins; Hearing Report Co. Has Lost Intellectual Property Rights Ruling Related to Xyrem Patent '963,2017-03-22 13:45:00-04:00,JAZZ,positive
693409.0,Jazz Pharma Gives Shorts A Wake-Up Call After JZP-110 Study Results,2017-03-20 13:43:00-04:00,JAZZ,neutral
693410.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,JAZZ,neutral
693411.0,UPDATE: Jazz Says 'Abstracts Accepted for Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017',2017-03-20 09:03:00-04:00,JAZZ,positive
693412.0,"Jazz Pharma Reports Results from Phase 3 TONES 3, TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea",2017-03-20 09:02:00-04:00,JAZZ,neutral
693413.0,Benzinga's Option Alert Recap From March 17,2017-03-17 16:43:00-04:00,JAZZ,positive
693414.0,Option Alert: Jazz Pharma Mar 31st 140 Calls: 650 @  ASK  $1.90: 650 traded vs 315 OI:  Earnings 5/9 After Close (est)  $134.52 Ref,2017-03-17 09:56:00-04:00,JAZZ,positive
693415.0,Jazz Pharmaceuticals Reports First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258,2017-03-15 16:06:00-04:00,JAZZ,neutral
693416.0,"Jazz Pharma Sees FY17 Adj. EPS $10.70-$11.30 vs $11.33 Est., Sales $1.625B-$1.7B vs $1.68B Est.",2017-02-28 16:06:00-05:00,JAZZ,neutral
693417.0,"Jazz Pharmaceuticals Reports Q4 Adj. $2.71 vs $2.65 Est., Sales $396.621M vs $398.3M Est.",2017-02-28 16:06:00-05:00,JAZZ,neutral
693418.0,"Earnings Scheduled For February 28, 2017",2017-02-28 04:54:00-05:00,JAZZ,neutral
693419.0,Vetr And Evercore Put Jazz Pharmaceuticals At Buy,2017-02-23 16:20:00-05:00,JAZZ,neutral
693420.0,"Benzinga's Top Upgrades, Downgrades For February 23, 2017",2017-02-23 09:39:00-05:00,JAZZ,positive
693421.0,Evercore ISI Group Initiates Coverage On Jazz Pharmaceuticals At Buy,2017-02-23 06:06:00-05:00,JAZZ,neutral
693422.0,Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Of JZP-110,2017-02-08 16:42:00-05:00,JAZZ,neutral
693423.0,Traders Attributing Weakness In Jazz Pharma To Updated Xyrem Label Posted Today With New Warning On Additional Neuropsychiatric Reactions,2017-01-27 14:14:00-05:00,JAZZ,negative
693424.0,Jazz Pharma Weakness Being Attributed To FDA Warning Letter For Porton Bio,2017-01-24 11:45:00-05:00,JAZZ,negative
693425.0,Jazz Pharma To Evaluate If Generic Xyrem's FDA Waiver Meets Required Legal Conditions,2017-01-18 13:23:00-05:00,JAZZ,positive
693426.0,15 Biggest Mid-Day Gainers For Wednesday,2017-01-18 12:37:00-05:00,JAZZ,neutral
693427.0,18 Stocks Moving In Wednesday's Pre-Market Session,2017-01-18 08:25:00-05:00,JAZZ,neutral
693428.0,Jazz Pharma Says Will Evaluate if FDA Waiver for Generic Xyrem Meets Legal Conditions Required,2017-01-18 06:21:00-05:00,JAZZ,positive
693429.0,Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide,2017-01-17 16:04:00-05:00,JAZZ,neutral
693430.0,"Cantor Fitzgerald Initiates Coverage On Jazz Pharmaceuticals plc - Ordinary Shares at Overweight, Announces $187.00 Target",2016-12-16 08:56:00-05:00,JAZZ,negative
693431.0,Jazz Pharmaceuticals Reports Completion Of Patient Enrollment For Phase 3 Study Of JZP-110,2016-11-28 16:06:00-05:00,JAZZ,neutral
693432.0,Jefferies London Health Care Conference Continues Today,2016-11-17 10:14:00-05:00,JAZZ,positive
693433.0,The Market In 5 Minutes: Trump Victory Spooks Stocks,2016-11-09 09:07:00-05:00,JAZZ,neutral
693434.0,A Peek Into The Markets: U.S. Stock Futures Tumble As Trump Wins 2016 Presidential Election,2016-11-09 07:20:00-05:00,JAZZ,positive
693435.0,"Keep an Eye on These 10 Stocks for November 9, 2016",2016-11-09 05:14:00-05:00,JAZZ,neutral
693436.0,"Jazz Pharmaceuticals Sees FY16 Rev. $1.485-$1.53B vs. Est. $1.51B, EPS $9.90-$10.30 vs. Est. $10.05",2016-11-08 16:06:00-05:00,JAZZ,neutral
693437.0,"Jazz Pharmaceuticals Reports Q3 EPS $2.57 vs. Est. $2.61, Rev. $374.181M vs. Est. $388.88M",2016-11-08 16:05:00-05:00,JAZZ,neutral
693438.0,"Earnings Scheduled For November 8, 2016",2016-11-08 04:27:00-05:00,JAZZ,neutral
693439.0,"Jazz Pharma Shares Ticking Over $102 Level as Hearing Cowen Making Mid-Day Comments on Name, Defending",2016-11-03 13:11:00-04:00,JAZZ,positive
693440.0,Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos  Expects to Complete NDA Submission by Early 2017,2016-10-03 08:31:00-04:00,JAZZ,neutral
693441.0,The Drug Price Increase Debate: Separating The Winners From The Losers,2016-09-27 11:23:00-04:00,JAZZ,positive
693442.0,Jazz Pharmaceuticals Reports That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea,2016-09-26 16:07:00-04:00,JAZZ,neutral
693443.0,Next Year Setting Up To Be Smooth For Jazz Pharmaceuticals,2016-09-21 13:04:00-04:00,JAZZ,neutral
693444.0,Shkreli Thinks The Mylan-Epipen Controversy Is 'Not Very Fair',2016-09-13 06:28:00-04:00,JAZZ,negative
693445.0,"Martin Shkreli Thinks Jazz Pharmaceuticals Could Be Worth $20 Billion, While Mast Therapeutics Is 'Worthless'",2016-09-12 11:39:00-04:00,JAZZ,positive
693446.0,"Martin Shkreli Says He's Looking at Jazz Pharma, Suggesting He Likes the Stock, Says 'Looks Like it Could Be Worth Double the Stock Price'",2016-09-12 08:31:00-04:00,JAZZ,positive
693447.0,5 Stocks Which Plummeted Three Days On Increasing Volume,2016-09-06 12:06:00-04:00,JAZZ,neutral
693448.0,Martin Shkreli @MartinShkreli Tweet: $JAZZ appears to be worth double the current stock price,2016-09-01 14:58:00-04:00,JAZZ,positive
693449.0,Here Are All The Big Biotech Mergers In 2016,2016-08-27 18:36:00-04:00,JAZZ,neutral
693450.0,"Janney Initiates Jazz Pharma At Neutral, Cites Potential Competition For 'Blockbuster Narcolepsy Franchise'",2016-08-25 15:52:00-04:00,JAZZ,positive
693451.0,Benzinga's Top Initiations,2016-08-25 09:29:00-04:00,JAZZ,positive
693452.0,Janney Capital Initiates Coverage on Jazz Pharmaceuticals at Neutral,2016-08-25 06:29:00-04:00,JAZZ,neutral
693453.0,Jazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report,2016-08-11 15:04:00-04:00,JAZZ,neutral
693454.0,Jazz Pharmaceuticals Remains On Goldman's Buy List,2016-08-10 10:28:00-04:00,JAZZ,neutral
693455.0,5 Stocks Shaken By Earnings In Tuesday's After-Hours Session,2016-08-09 17:36:00-04:00,JAZZ,negative
693456.0,"Jazz Pharmaceuticals Misses Earnings, Cuts Guidance",2016-08-09 16:22:00-04:00,JAZZ,negative
693457.0,"Jazz Pharma Reports Q2 EPS $2.63 vs $2.80 Est, Rev $381.16M vs $376.42M Est",2016-08-09 16:07:00-04:00,JAZZ,neutral
693458.0,"Earnings Scheduled For August 9, 2016",2016-08-09 04:04:00-04:00,JAZZ,neutral
693459.0,"Jazz Pharmaceuticals Announces US Centers for Medicare and Medicaid Services has Granted New Technology Add-on Payment for Defitelio; NTAP Payment for Defitelio has been Established at $75,900",2016-08-03 04:35:00-04:00,JAZZ,positive
693460.0,Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies,2016-07-28 16:05:00-04:00,JAZZ,positive
693461.0,"Cowen Says End Of Uncertainty Is Nearing For IPR Decision On Xyrem, Should Be Value Creating; Continue To Add Shares",2016-07-28 15:04:00-04:00,JAZZ,positive
693462.0,Traders Attributing Spike in Jazz Due to Favorable Patent Ruling Involving Xyrem,2016-07-28 11:40:00-04:00,JAZZ,positive
693463.0,Jazz Pharmaceuticals Spiking HIgher,2016-07-28 11:29:00-04:00,JAZZ,neutral
693464.0,Jazz Spikes to High of $142.86 on Volume,2016-07-28 11:29:00-04:00,JAZZ,neutral
693465.0,What Is An Options Sweep?,2016-07-22 12:05:00-04:00,JAZZ,neutral
693466.0,Watch These 7 Huge Call Purchases In Friday Trade,2016-07-22 02:24:00-04:00,JAZZ,positive
693467.0,Jazz Pharma Spikes to High of $145.55 on Vol,2016-07-21 13:47:00-04:00,JAZZ,neutral
693468.0,Option Alert: JAZZ Aug16 146 Calls Sweep: 676 @  ASK  $6.20: 676 traded vs 0 OI:  Earnings 8/3  $144.51 Ref,2016-07-21 13:45:00-04:00,JAZZ,positive
693469.0,Jazz Pharmaceuticals Announces Results of Tender Offer  for Celator Pharmaceuticals Shares,2016-07-12 04:34:00-04:00,JAZZ,positive
693470.0,Celator Pharmaceuticals Announces Putative Class-action Lawsuit Challenging Acquisition by Jazz Pharmaceuticals,2016-06-30 06:13:00-04:00,JAZZ,negative
693471.0,BMO Sees Jazz Pharma As 'A Rare Breed In Specialty Pharma',2016-06-29 16:32:00-04:00,JAZZ,neutral
693472.0,BMO Capital Initiates Coverage on Jazz Pharmaceuticals at Outperform,2016-06-29 06:26:00-04:00,JAZZ,neutral
693473.0,Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals Acquisition,2016-06-27 03:57:00-04:00,JAZZ,neutral
693474.0,"Jazz Pharma Says New Data on JZP-110 Showed Each Doses Had Consistently Lower Ratings on Primary Endpoint of Peak Liking at the Moment, Secondary Endpoints of Overall Drug Liking, Willingness to Take",2016-06-14 09:06:00-04:00,JAZZ,positive
693475.0,"Goldman Initiates Specialty Pharma At Neutral, Highlights 'A Confluence Of Concerns'",2016-06-06 13:22:00-04:00,JAZZ,neutral
693476.0,Goldman Sees 26% Upside In Jazz Pharma Shares,2016-06-06 10:29:00-04:00,JAZZ,positive
693477.0,Benzinga's Top Initiations,2016-06-06 09:29:00-04:00,JAZZ,positive
693478.0,"Goldman Sachs Initiates Coverage on Jazz Pharmaceuticals at Buy, Announces $196.00 PT",2016-06-06 07:22:00-04:00,JAZZ,neutral
693479.0,"SunTrust On Jazz's Celator Purchase: 'Makes Strategic, Financial Sense'",2016-06-02 15:04:00-04:00,JAZZ,neutral
693480.0,8 Mergers You Might Have Missed On Tuesday,2016-06-01 11:15:00-04:00,JAZZ,negative
693481.0,Mid-Afternoon Market Update: Dow Drops 125 Points; Cliffs Natural Resources Shares Spike Higher,2016-05-31 14:33:00-04:00,JAZZ,positive
693482.0,Mid-Day Market Update: Dow Falls Over 50 Points; Celator Pharmaceuticals Shares Jump After Acquisition Announcement By Jazz Pharmaceuticals,2016-05-31 12:07:00-04:00,JAZZ,positive
693483.0,Benzinga's Volume Movers,2016-05-31 10:40:00-04:00,JAZZ,neutral
693484.0,Stocks Hitting 52-Week Highs,2016-05-31 10:15:00-04:00,JAZZ,neutral
693485.0,Mid-Morning Market Update: Markets Edge Higher; Medtronic Earnings Top Views,2016-05-31 10:04:00-04:00,JAZZ,positive
693486.0,Today's Top 10 Pre-Market Gainers,2016-05-31 09:28:00-04:00,JAZZ,positive
693487.0,The Market In 5 Minutes: Welcome Back,2016-05-31 08:46:00-04:00,JAZZ,positive
693488.0,Celator Surges 70% After Acquisition Announcement By Jazz Pharmaceuticals,2016-05-31 08:28:00-04:00,JAZZ,neutral
693489.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-05-31 08:21:00-04:00,JAZZ,neutral
693490.0,Jazz Pharmaceuticals to Acquire Celator Pharmaceuticals for $30.25/Share in Cash,2016-05-31 04:05:00-04:00,JAZZ,neutral
693491.0,How Big Pharma Uses Charity Programs To Cover Drug Price Hikes,2016-05-20 15:46:00-04:00,JAZZ,positive
693492.0,"Jazz Pharma On Track To Report Top-Line, Late-Stage Results Of JZP-110 By December",2016-05-17 16:11:00-04:00,JAZZ,neutral
693493.0,The Market In 5 Minutes: Don't Stop Me Now,2016-05-11 09:34:00-04:00,JAZZ,positive
693494.0,"Jazz Pharma Sees EPS $11.10-$11.50 Vs Est $11.14, Sales $1.490B-$1.550B Vs Est $1.53B",2016-05-10 16:07:00-04:00,JAZZ,neutral
693495.0,"Jazz Pharma Reports Adj EPS $2.26 Vs Est $2.31, Sales $336M Vs Est $338.86M",2016-05-10 16:05:00-04:00,JAZZ,neutral
693496.0,"Earnings Scheduled For May 10, 2016",2016-05-10 04:29:00-04:00,JAZZ,neutral
693497.0,"The Market In 5 Minutes: Monday, April 25, 2016",2016-04-25 09:55:00-04:00,JAZZ,neutral
693498.0,Benzinga's Top Upgrades,2016-04-25 08:53:00-04:00,JAZZ,positive
693499.0,"SunTrust Robinson Humphrey Upgrades Jazz Pharmaceuticals to Buy, Raises PT to $200.00",2016-04-25 06:55:00-04:00,JAZZ,neutral
693500.0,Jazz Pharma Investors: Did You Catch This Favorable Ruling?,2016-04-13 11:51:00-04:00,JAZZ,positive
693501.0,Benzinga's Volume Movers,2016-04-13 10:21:00-04:00,JAZZ,neutral
693502.0,"Fast Money Picks For April 8: Buy KB Home, Short The Russell 2000",2016-04-08 06:01:00-04:00,JAZZ,neutral
693503.0,What Does Jazz Pharma's Latest FDA Approval Mean?,2016-03-31 10:32:00-04:00,JAZZ,positive
693504.0,UPDATE: Jazz Pharmaceuticals Announces Webcast for Defitelio Investor Update,2016-03-30 14:44:00-04:00,JAZZ,neutral
693505.0,"UPDATE: Jazz Pharmaceuticals Defitelio Is First, Only FDA-Approved Therapy For Patients With This Rare Complication",2016-03-30 14:35:00-04:00,JAZZ,neutral
693506.0,Jazz Pharma Announces FDA Approval of Defitelio,2016-03-30 14:34:00-04:00,JAZZ,positive
693507.0,"Shares of Jazz Pharma Spike Higher as Hearing FDA Has Approved First Treatment for Rare Disease in Patients Who Received Stem Cell Transplant from Blood, Bone Marrow",2016-03-30 12:14:00-04:00,JAZZ,positive
693508.0,What's Going On With Kyle Bass And Biogen?,2016-03-23 14:23:00-04:00,JAZZ,neutral
693509.0,Jazz Pharma Falls After Q4 Sales Miss Street View,2016-02-24 15:39:00-05:00,JAZZ,negative
693510.0,"Stifel Nicolaus Maintains Buy on Jazz Pharmaceuticals, Lowers PT to $200.00",2016-02-24 08:20:00-05:00,JAZZ,negative
693511.0,Earnings Recap For February 23,2016-02-23 16:27:00-05:00,JAZZ,neutral
693512.0,Jazz Pharma Sees FY 2016 EPS $10.90-$11.30 Vs Est $11.42 & Sales $1.49B-$1.55B Vs Est $1.54B,2016-02-23 16:07:00-05:00,JAZZ,neutral
693513.0,"Jazz Pharmaceuticals Reports Q4 EPS $2.60 vs. Est. $2.60, Rev. $340.881M vs. Est. $349M",2016-02-23 16:06:00-05:00,JAZZ,neutral
693514.0,"Earnings Scheduled For February 23, 2016",2016-02-23 03:14:00-05:00,JAZZ,neutral
693515.0,Wells Fargo Initiates Coverage on Jazz Pharmaceuticals at Outperform,2016-02-19 08:40:00-05:00,JAZZ,positive
693516.0,"Patrick Enright Sells 10,000 Shares Of Jazz Pharmaceutical @$117.92/Share -Form 4",2016-02-12 17:00:00-05:00,JAZZ,positive
693517.0,"UPDATE: Jazz Pharma Phase 3 Trial Result for Defibrotide Show Improved Survival, Complete Response Compared with Historical Controls",2016-02-01 09:26:00-05:00,JAZZ,positive
693518.0,Jazz Pharmaceuticals Phase 3 Defibrotide Trial Published Online In BLOOD,2016-02-01 09:08:00-05:00,JAZZ,neutral
693519.0,"Over 1,000 Stocks On The NYSE Just Hit 52-Week Lows",2016-01-20 13:53:00-05:00,JAZZ,negative
693520.0,3 Stocks To Watch In Thursday's After-Hours Session,2016-01-14 16:53:00-05:00,JAZZ,neutral
693521.0,Kyle Bass Explains The 'Patent Trolls' Situation In The Pharma Industry,2016-01-02 20:38:00-05:00,JAZZ,neutral
693522.0,"Martin Shkreli-KaloBios Saga An Example Of How Penny Stocks Can Be Misunderstood, Tim Sykes Says",2015-12-17 16:44:00-05:00,JAZZ,negative
693523.0,"Bernstein Initiates Coverage on Jazz Pharmaceuticals at Market Perform, Announces $160.00 PT",2015-11-25 09:16:00-05:00,JAZZ,neutral
693524.0,Benzinga's Top Downgrades,2015-11-10 08:51:00-05:00,JAZZ,positive
693525.0,"Mizuho Securities Downgrades Jazz Pharmaceuticals to Neutral, Lowers PT to $140.00",2015-11-10 06:38:00-05:00,JAZZ,positive
693526.0,"Jazz Pharma Sees FY15 Adj. EPS $9.45-$9.60 vs $9.67 Est., Sales $1.32B-$1.34B vs $1.36B est.",2015-11-09 16:27:00-05:00,JAZZ,neutral
693527.0,"Jazz Pharma Reports Q3 Adj. EPS $2.52 vs $2.56 Est., Sales $341M vs $348M Est.",2015-11-09 16:26:00-05:00,JAZZ,neutral
693528.0,"Earnings Scheduled For November 9, 2015",2015-11-09 04:03:00-05:00,JAZZ,neutral
693529.0,2 Hot Upcoming Healthcare Earnings Calls,2015-11-05 15:00:00-05:00,JAZZ,neutral
693530.0,Hearing Jazz Pharma Intellectual Property Right Decision Is Positive,2015-10-15 15:51:00-04:00,JAZZ,positive
693531.0,"Northland Starts Jazz Pharma, Mallinckrodt, Shire With Outperform Ratings",2015-10-14 09:36:00-04:00,JAZZ,neutral
693532.0,"Northland Securities Initiates Coverage on Jazz Pharmaceuticals at Outperform, Announces $200.00 PT",2015-10-14 08:14:00-04:00,JAZZ,positive
693533.0,How To Invest During Biotech's Latest Crisis,2015-10-09 11:25:00-04:00,JAZZ,negative
693534.0,"Mizuho Securities Initiates Coverage on Jazz Pharmaceuticals at Buy, Announces $164.00 PT",2015-10-08 19:23:00-04:00,JAZZ,positive
693535.0,"Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You",2015-10-05 15:06:00-04:00,JAZZ,positive
693536.0,Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease,2015-09-30 08:30:00-04:00,JAZZ,positive
693537.0,"Jazz Pharma Reports Q1 EPS $2.41 Vs Est $2.41, Sales $333.7M Vs Est $335.36M",2015-08-05 16:10:00-04:00,JAZZ,neutral
693538.0,The Wall Street Research Making Waves Today,2015-07-31 12:22:00-04:00,JAZZ,neutral
693539.0,Jazz Pharma Could Be Worth Over $200 If Xyrem Adds Long-Term Value: Here's How,2015-07-31 10:56:00-04:00,JAZZ,positive
693540.0,ETFs For The Next Pharma Takeover Candidates,2015-07-28 13:08:00-04:00,JAZZ,neutral
693541.0,"Earning & Economic Calendar for Wednesday July 15, 2015",2015-07-15 05:38:00-04:00,JAZZ,neutral
693542.0,"Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz",2015-07-09 08:56:00-04:00,JAZZ,positive
693543.0,"Jazz Pharma Still Loved At UBS, Firm Hikes Price Target To $210",2015-06-29 11:11:00-04:00,JAZZ,positive
693544.0,Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic,2015-06-09 08:04:00-04:00,JAZZ,negative
693545.0,Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110,2015-06-08 09:05:00-04:00,JAZZ,neutral
693546.0,Jazz Pharma. To Present Abstracts from Ongoing Evaluations of Xyrem at SLEEP 2015,2015-06-04 09:06:00-04:00,JAZZ,neutral
693547.0,Who's The Next Big Pharma Acquisition?,2015-05-29 11:20:00-04:00,JAZZ,neutral
693548.0,8-K from Ampio Pharma Shows Co. Has Purchased Jazz Pharma's ProstaScint for $1M at Closing Plus Added $500K Payable Within Five Days After Transfer,2015-05-27 16:16:00-04:00,JAZZ,neutral
693549.0,"Jazz Pharma Reports Q1 EPS $1.99 Vs Est $2.14, Sales $309.3M Vs Est $308.29M",2015-05-07 16:06:00-04:00,JAZZ,neutral
693550.0,High Expectations For Jazz Pharmaceuticals,2015-05-07 15:22:00-04:00,JAZZ,neutral
693551.0,"Earning & Economic Calendar for Thursday May 7, 2015",2015-05-07 04:50:00-04:00,JAZZ,neutral
693552.0,"Earnings Scheduled For May 7, 2015",2015-05-07 04:41:00-04:00,JAZZ,neutral
693553.0,Oppenheimer Analysts Pick A Top Stock From Each Market Sector,2015-04-27 12:16:00-04:00,JAZZ,positive
693554.0,Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent,2015-04-20 16:09:00-04:00,JAZZ,positive
693555.0,Why This Trader Is Worried About Jazz Pharmaceuticals,2015-04-18 10:41:00-04:00,JAZZ,negative
693556.0,How Much Further Can Jazz Pharmaceuticals Fall?,2015-04-08 16:40:00-04:00,JAZZ,neutral
693557.0,Bass Challenges Jazz Pharmaceuticals Patent for Xyrem -DJ,2015-04-07 10:01:00-04:00,JAZZ,positive
693558.0,"Shares of Shire, Jazz Pharma Quiet Following Bloomberg Headlines Suggesting Sigma-Tau's Rare Diseases Unit Could Draw Interest",2015-03-30 11:13:00-04:00,JAZZ,positive
693559.0,Oppenheimer: Bullish Technical Analysis Of 5 Healthcare Names,2015-03-18 08:10:00-04:00,JAZZ,neutral
693560.0,"Jazz Pharmaceuticals Says on February 27, 2015, FDA Notified Co's Unit of Approval of Risk Evaluation and Mitigation Strategy for Xyrem, FDA Concluded Xyrem REMS Meets Applicable Statutory Standards",2015-03-02 08:21:00-05:00,JAZZ,positive
693561.0,Heavy News Day For Several Biotech Stocks,2015-02-25 15:34:00-05:00,JAZZ,neutral
693562.0,8 Stories JP Morgan Is Watching Today,2015-02-25 12:28:00-05:00,JAZZ,positive
693563.0,Benzinga's Top #PreMarket Losers,2015-02-25 08:19:00-05:00,JAZZ,negative
693564.0,"Jazz Pharmaceuticals Sinks On Outlook, Halt In Drug Trial",2015-02-24 20:37:00-05:00,JAZZ,neutral
693565.0,"Jazz Pharmaceuticals Reports jeffrey Tobias, Executive VP of R&D, Chief Medical Officer, to Retire",2015-02-24 16:31:00-05:00,JAZZ,neutral
693566.0,"Jazz Pharma Reports Q4 EPS $2.44 Vs Est $2.31, Sales $328.1M Vs Est $320.27M",2015-02-24 16:06:00-05:00,JAZZ,neutral
693568.0,Benzinga's Top Initiations,2015-02-20 09:34:00-05:00,JAZZ,positive
693569.0,BMO Capital Initiates Jazz Pharmaceuticals At Outperform,2015-02-20 08:38:00-05:00,JAZZ,neutral
693570.0,"BMO Capital Initiates Coverage on Jazz Pharmaceuticals at Outperform, Announces $200.00 PT",2015-02-20 06:47:00-05:00,JAZZ,neutral
693571.0,Stifel: Now's The Time To Buy These 3 Stocks,2015-02-19 13:51:00-05:00,JAZZ,neutral
693572.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,JAZZ,neutral
693573.0,"Jazz Pharmaceuticals Director Enright Sells 10,000 Shares @$160.25/Share -Form 4",2015-01-07 16:05:00-05:00,JAZZ,positive
693574.0,Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide,2014-12-11 16:07:00-05:00,JAZZ,neutral
693575.0,"Jazz Pharma, Concert Pharma Report JZP-386 Program Update",2014-12-09 08:30:00-05:00,JAZZ,neutral
693576.0,"Great News For Biogen, But What's Next For The Stock?",2014-12-03 12:36:00-05:00,JAZZ,positive
693577.0,Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease At ASH,2014-12-02 16:07:00-05:00,JAZZ,neutral
693578.0,Jazz Pharmaceuticals Announces First Patients Enrolled In Phase 3 Trial Of Xyrem,2014-12-02 16:07:00-05:00,JAZZ,neutral
693579.0,Riding The Bull Market With These 2 Momentum ETFs,2014-11-20 15:10:00-05:00,JAZZ,neutral
693580.0,This Biotech's Earnings Are Sending It Toward New Highs,2014-11-05 11:57:00-05:00,JAZZ,neutral
693581.0,Jazz Pharmaceuticals plc Sees FY2014 EPS $8.20-8.35 vs $8.17 Est; Sees Sales $1.15M-1.17M,2014-11-04 16:27:00-05:00,JAZZ,neutral
693582.0,Jazz Pharmaceuticals plc Reports Q3 EPS of $2.33 vs $2.22 Est; Revenue of $306.58M vs $302.48M Est,2014-11-04 16:24:00-05:00,JAZZ,neutral
693583.0,"Earnings Scheduled For November 4, 2014",2014-11-04 05:31:00-05:00,JAZZ,neutral
693584.0,"Jazz Pharmaceuticals Director Enright Sells 10,000 Shares @$160.56/Share -Form 4",2014-10-08 07:15:00-04:00,JAZZ,positive
693585.0,Jazz Pharma Shares Move Lower; May be Attributed to Article from Irish Times: 'OECD plan likely to prompt changes to Irish corporate tax regime',2014-09-16 11:43:00-04:00,JAZZ,neutral
693586.0,"Jazz Pharmaceuticals Up On Allergan, Inc. Rumor",2014-09-05 15:53:00-04:00,JAZZ,neutral
693587.0,Hearing Deal Reporter Says Jazz Takeover Target of Allergan,2014-09-05 10:57:00-04:00,JAZZ,neutral
693588.0,"Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs ",2014-08-19 16:35:00-04:00,JAZZ,positive
693589.0,JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition',2014-08-19 14:02:00-04:00,JAZZ,positive
693590.0,"UPDATE: Valeant, Jazz Shares Move Higher on WSJ Report of Potential Allergan Deal for Salix",2014-08-19 13:12:00-04:00,JAZZ,positive
693591.0,Jazz Pharma Shares Continue Higher for Fifth Session in a Row; JP Morgan Earlier Initiated Coverage with Overweight Rating,2014-08-19 11:55:00-04:00,JAZZ,positive
693592.0,Jazz Pharma Announces $500M Note Offering,2014-08-06 16:05:00-04:00,JAZZ,neutral
693593.0,Morning Market Movers ,2014-08-06 09:47:00-04:00,JAZZ,neutral
693594.0,Jazz Pharmaceuticals Spikes In #PreMarket On Q2 Beat; Boosts Revenue Outlook,2014-08-06 09:33:00-04:00,JAZZ,positive
693595.0,Benzinga's Top #PreMarket Gainers,2014-08-06 08:12:00-04:00,JAZZ,positive
693596.0,Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower,2014-08-05 16:46:00-04:00,JAZZ,negative
693597.0,Benzinga's Top Initiations,2014-07-23 09:13:00-04:00,JAZZ,positive
693598.0,Buckingham Research Initiates Jazz Pharmaceuticals With Buy,2014-07-23 07:16:00-04:00,JAZZ,neutral
693599.0,"Buckingham Research Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces $215.00 PT",2014-07-23 06:46:00-04:00,JAZZ,neutral
693600.0,"SunTrust Robinson Humphrey Initiates Coverage on Jazz Pharmaceuticals plc at Neutral, Announces $158.00 PT",2014-07-16 19:19:00-04:00,JAZZ,neutral
693601.0,Jazz Pharmaceuticals Receives Patent Entitled 'Method of Administration of Gamma Hydroxybutyrate with Monocarboxylate Transporters' -8-K,2014-07-08 06:13:00-04:00,JAZZ,positive
693602.0,"Jazz Pharma Reports Deal to Buy Rights to Defibrotide, Sigma-Tau Will Get Upfront Payment $75M, Milestone Payments $25M, Could Also Get Up to Added $150M Based on Timing",2014-07-02 08:01:00-04:00,JAZZ,neutral
693603.0,"Cramer Says Eaton, TE Connectivity, Pentair, Tyco, Alkermes, Jazz Pharma, Weatherford May be Takeover Targets, Similar Situations to Covidien Regarding Tax Benefit",2014-06-16 18:23:00-04:00,JAZZ,positive
693604.0,"Market Wrap For June 11: Momentum Hit, Dow Suffers Triple Digit Loss",2014-06-11 16:36:00-04:00,JAZZ,negative
693605.0,Wells Fargo Initiates Coverage On The Pharmaceutical Space,2014-06-11 11:36:00-04:00,JAZZ,positive
693606.0,Wells Fargo Initiates Coverage on Jazz Pharmaceuticals plc at Outperform,2014-06-11 06:48:00-04:00,JAZZ,positive
693607.0,"UPDATE: Jazz Said Both Primary, Secondary Endpoints Met in Phase 2b Trial of JZP-110",2014-06-02 15:12:00-04:00,JAZZ,neutral
693608.0,Jazz Pharma Presented Phase 2b Data for JZP-110 for Treatment of EDS Systems in Adults with Narcolepsy,2014-06-02 15:12:00-04:00,JAZZ,neutral
693609.0,"UPDATE: Jazz Pharma Release Shows All Primary/Secondary Endpoints Were Met in Study, JZP-110 Was Generally Well Tolerated",2014-06-02 14:48:00-04:00,JAZZ,positive
693610.0,Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy,2014-06-02 14:41:00-04:00,JAZZ,neutral
693611.0,Market Wrap For May 27: S&P 500 Closes At New Record High After Holiday Weekend,2014-05-27 16:48:00-04:00,JAZZ,positive
693612.0,Jazz Pharmaceuticals Announces Russell Cox COO,2014-05-19 14:00:00-04:00,JAZZ,neutral
693613.0,"13F Filing from Stephen Mandel's Lone Pine Shows New Stakes in Actavis, Adobe, Jazz Pharma, Liquidated Positions in AmEx, Mead Johnson, Dollar Tree, Kinder Morgan",2014-05-15 16:55:00-04:00,JAZZ,positive
693614.0,Five Star Biotech Stock Watch: Jazz Pharmaceuticals,2014-05-14 14:09:00-04:00,JAZZ,neutral
693615.0,Jazz Pharmaceuticals plc Sees FY2014 EPS $8.00-8.25 vs $8.20 Est; Sees Sales $1.10B-1.16B vs $1.13B Est,2014-05-08 16:38:00-04:00,JAZZ,neutral
693616.0,Jazz Pharmaceuticals plc Reports Q1 EPS of $1.61 vs $1.79 Est; Revenue of $246.90M vs $254.86M Est,2014-05-08 16:05:00-04:00,JAZZ,neutral
693617.0,Market Wrap For April 17: Mixed Earnings Drag The Dow Lower While S&P 500 & Nasdaq End Positive,2014-04-17 16:42:00-04:00,JAZZ,positive
693618.0,Benzinga's Top Initiations,2014-04-17 07:53:00-04:00,JAZZ,positive
693619.0,"Canaccord Genuity Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces $163.00 PT",2014-04-17 07:47:00-04:00,JAZZ,neutral
693620.0,Market Wrap For March 31: Stocks Rally As Yellen Confirms Support For Economy,2014-03-31 16:37:00-04:00,JAZZ,positive
693621.0,"UPDATE: Jazz Pharmaceuticals, Gentium Announce European Commercial Launch of Defitelio",2014-03-31 08:09:00-04:00,JAZZ,neutral
693622.0,"Jazz Pharmaceuticals, Gentium Announce European Commercial Launch ff First Approved Life-Saving Treatment for Severe Hepatic Veno-Occlusive Disease",2014-03-31 08:04:00-04:00,JAZZ,positive
693623.0,UPDATE: Ariad Pharmaceuticals Shares Rise 5% Premarket Following Thursday's UK Daily Mail Report of Rumored $20 Bid from Jazz Pharmaceuticals,2014-03-28 06:29:00-04:00,JAZZ,positive
693624.0,Daily Mail Reports Jazz Pharmaceuticals Willing to Pay $20/Share for Ariad,2014-03-27 19:23:00-04:00,JAZZ,negative
693625.0,Market Wrap For March 7: Markets Cap Off Positive Week With Small Gains,2014-03-07 16:31:00-05:00,JAZZ,positive
693626.0,"Barclays Reinstates Overweight on Jazz Pharmaceuticals plc, Announces $200.00 PT",2014-03-07 07:31:00-05:00,JAZZ,negative
693627.0,Form 8-K from Jazz Pharma Shows Court Issued Order on March 5th Granting a Stay of Claims Related to '730 Patent Family,2014-03-06 17:32:00-05:00,JAZZ,positive
693628.0,"Jazz Reports Two Investors Exercised 947,867 Warrants for Shares",2014-02-28 07:12:00-05:00,JAZZ,positive
693629.0,"Morning Movers for Feb. 26, 2014: ANIK, JAKK, ZAGG, PLUG, TASR, ANF Moving Higher, FST, UTIW, SEAC, FSLR, DWA Lower",2014-02-26 09:40:00-05:00,JAZZ,negative
693630.0,"Cantor Fitzgerald Downgrades Jazz Pharmaceuticals plc to Hold, Raises PT to $182.00",2014-02-26 07:57:00-05:00,JAZZ,neutral
693631.0,"Stifel Nicolaus Maintains Buy on Jazz Pharmaceuticals plc, Raises PT to $195.00",2014-02-26 06:58:00-05:00,JAZZ,neutral
693632.0,"Jazz Pharma Posts 12% Increase in Q4 Profit, But Still Misses; Guides Above the Street",2014-02-25 18:24:00-05:00,JAZZ,positive
693633.0,UPDATE: Jazz Pharmaceuticals Shares Fall 4% After-Hours on Earnings Miss,2014-02-25 16:21:00-05:00,JAZZ,positive
693634.0,"Jazz Pharma Says CFO Stepping Down, Names Matthew Young as Replacement",2014-02-25 16:08:00-05:00,JAZZ,neutral
693635.0,Jazz Pharmaceuticals plc Sees FY2014 EPS $8.00-8.25 vs $8.07 Est; Sees Sales $1.09B-1.15B vs $1.08B Est,2014-02-25 16:07:00-05:00,JAZZ,neutral
693636.0,Jazz Pharmaceuticals plc Reports Q4 EPS of $1.72 vs $1.78 Est; Revenue of $235.80M vs $238.12M Est,2014-02-25 16:06:00-05:00,JAZZ,neutral
693637.0,Earning and Economic Calendar for Tuesday February 25 2014,2014-02-25 06:37:00-05:00,JAZZ,neutral
693638.0,"Earnings Scheduled For February 25, 2014",2014-02-25 04:28:00-05:00,JAZZ,neutral
693639.0,"Option Alert: Jazz Pharmaceutical June $175 Call; 1,751 Contracts Traded vs 148 OI; Currently $163.48",2014-02-12 12:56:00-05:00,JAZZ,positive
693640.0,Gentium Holders Sue to Stop Jazz Pharma Purchase,2014-01-15 16:33:00-05:00,JAZZ,negative
693641.0,Form 8-K from Jazz Pharma Shows Reaffirmed Outlook,2014-01-14 17:29:00-05:00,JAZZ,neutral
693642.0,Jazz Announces Acquisition of Rights to ADX-N05 from Aerial Biopharma for $125M Upfront Payment,2014-01-13 08:08:00-05:00,JAZZ,neutral
693643.0,Market Wrap For January 2: Markets Begin 2014 on Negative Note,2014-01-02 16:45:00-05:00,JAZZ,negative
693644.0,Market Wrap For December 20: Markets Gain On GDP Data ,2013-12-20 16:44:00-05:00,JAZZ,positive
693645.0,Mid-Afternoon Market Update: Textron Rises as Markets Rise Across the Board,2013-12-20 15:49:00-05:00,JAZZ,neutral
693646.0,Mid-Day Market Update: Red Hat Surges On Upbeat Results; CarMax Shares Decline,2013-12-20 12:47:00-05:00,JAZZ,positive
693647.0,Mid-Morning Market Update: Markets Rally; BlackBerry Posts Q3 Loss,2013-12-20 10:42:00-05:00,JAZZ,negative
693648.0,"ETF Outlook for Friday, December 20 (REM, USO, IBB, FCG)",2013-12-20 07:11:00-05:00,JAZZ,neutral
693649.0,"Benzinga's M&A Chatter for Thursday December 19, 2013",2013-12-19 17:41:00-05:00,JAZZ,neutral
693650.0,PREVIEW: Gentium to Resume Trading at 5:15 PM ET,2013-12-19 16:50:00-05:00,JAZZ,neutral
693651.0,Jazz Pharmaceuticals Trading at $118  Following Announcement of Gentium Acquisition,2013-12-19 16:48:00-05:00,JAZZ,neutral
693652.0,Jazz Pharmaceuticals to Acquire Gentium for $57.00/Share ,2013-12-19 16:45:00-05:00,JAZZ,neutral
693653.0,Market Wrap For December 16: Dow Posts Triple Point Gain Ahead of Fed Meeting,2013-12-16 16:55:00-05:00,JAZZ,positive
693654.0,"Goldman Sachs Downgrades Jazz Pharmaceuticals plc to Neutral, Raises PT to $123.00",2013-12-16 08:44:00-05:00,JAZZ,neutral
693655.0,"Cantor Fitzgerald Boosts Price Target on Jazz Pharma from $106 to $145, Maintains Buy",2013-12-04 08:23:00-05:00,JAZZ,positive
693656.0,"Market Wrap For November 25: Nasdaq Breaks 4,000 Level For First Time Since 2000",2013-11-25 16:57:00-05:00,JAZZ,neutral
693657.0,"RF Lafferty Lifts Target on Jazz Pharma from $102 to $118, Maintains Buy",2013-11-13 14:57:00-05:00,JAZZ,neutral
693658.0,Jazz Pharmaceuticals Crosses Above $100 ,2013-11-11 11:55:00-05:00,JAZZ,neutral
693659.0,Jazz Pharmaceuticals plc Sees FY2013 EPS $6.30-6.40 vs $6.30 Est; Sees Sales $867.0M-877.0M vs $872.10M Est,2013-11-05 17:09:00-05:00,JAZZ,neutral
693660.0,Jazz Pharmaceuticals plc Sees FY2013 EPS $6.30-6.40 vs $6.30 Est; Sees Sales $867.0M-877.0M vs $872.90M Est,2013-11-05 16:55:00-05:00,JAZZ,neutral
693661.0,Jazz Pharmaceuticals plc Reports Q3 EPS of $1.78 vs $1.67 Est; Revenue of $232.20M vs $227.38M Est,2013-11-05 16:54:00-05:00,JAZZ,neutral
693662.0,"Earnings Scheduled For November 5, 2013",2013-11-05 04:29:00-05:00,JAZZ,neutral
693663.0,5 Healthcare Stocks With The Highest EPS Estimates For The Next Quarter,2013-10-02 10:35:00-04:00,JAZZ,neutral
693664.0,"Goldman Sachs Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces $105.00 PT",2013-09-17 07:09:00-04:00,JAZZ,neutral
693665.0,"Option Alert: Jazz Pharmaceuticals September 60 Put; Block Trade: 2,000 Contracts @$0.10; Currently $81.68",2013-08-13 13:44:00-04:00,JAZZ,negative
693666.0,UPDATE: Stifel Nicolaus Raises PT on Jazz Pharmaceuticals Following 2Q13 Revenue Report,2013-08-07 10:36:00-04:00,JAZZ,neutral
693667.0,Jazz Pharmaceuticals plc Reports Q2 EPS of $1.43 vs $1.52 Est,2013-08-06 16:12:00-04:00,JAZZ,neutral
693668.0,Cantor Fitzgerald Reiterates Jazz Pharmaceuticals at Buy on Favorable FDA Developments,2013-07-09 08:37:00-04:00,JAZZ,positive
693669.0,UPDATE: Stifel Nicolaus Initiates  Jazz Pharmaceuticals at Buy on Multiple Positive Factors,2013-05-31 09:18:00-04:00,JAZZ,positive
693670.0,"Stifel Nicolaus Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces $80.00 PT",2013-05-31 08:37:00-04:00,JAZZ,neutral
693671.0,Stifel Nicolaus Initiates Coverage on Jazz Pharmaceuticals plc at Buy,2013-05-31 07:54:00-04:00,JAZZ,neutral
693672.0,Guggenheim Suggesting Jazz Pharma Could be Acquisition Target,2013-05-22 13:35:00-04:00,JAZZ,neutral
693673.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter ,2013-05-15 04:13:00-04:00,JAZZ,positive
693674.0,Jazz Pharmaceuticals plc Raises FY2013 EPS Guidance from $5.70-5.90 to $6.10-6.30 vs $5.88 Est; Sees Sales $823.0M-853.0M vs $825.50M Est,2013-05-07 16:23:00-04:00,JAZZ,neutral
693675.0,Jazz Pharmaceuticals Announces $200M Buyback,2013-05-07 16:15:00-04:00,JAZZ,neutral
693676.0,Jazz Pharmaceuticals plc Reports Q1 EPS of $1.37 vs $1.35 Est,2013-05-07 16:14:00-04:00,JAZZ,neutral
693677.0,"Earnings Scheduled For May 7, 2013",2013-05-07 04:13:00-04:00,JAZZ,neutral
693678.0,"JMP Securities Initiates Coverage on Jazz Pharmaceuticals plc at Market Outperform, Announces $66.00 PT",2013-03-28 08:49:00-04:00,JAZZ,positive
693679.0,"Citigroup Maintains Buy on Jazz Pharmaceuticals plc, Raises PT to $75.00",2013-03-12 07:02:00-04:00,JAZZ,neutral
693680.0,UPDATE: Cantor Fitzgerald Initiates Jazz Pharmaceuticals at Buy on Xyrem Outlook,2013-03-11 07:51:00-04:00,JAZZ,neutral
693681.0,Benzinga's Top Initiations,2013-03-11 07:40:00-04:00,JAZZ,positive
693682.0,"Cantor Fitzgerald Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces $86.00 PT",2013-03-11 06:42:00-04:00,JAZZ,neutral
693683.0,Jazz Pharma Prices 5.375M Shares at $58.50/Share,2013-03-05 09:05:00-05:00,JAZZ,positive
693684.0,Jazz Announces 5.375M Share Secondary Offering,2013-03-04 16:50:00-05:00,JAZZ,positive
693685.0,UPDATE: Piper Jaffray Raises PT to $69 on Jazz Pharmaceuticals; Growth Visibility is Solid,2013-02-27 11:37:00-05:00,JAZZ,positive
693686.0,"Piper Jaffray Maintains Overweight on Jazz Pharmaceuticals plc, Raises PT to $69.00",2013-02-27 08:03:00-05:00,JAZZ,negative
693687.0,Jazz Pharmaceuticals plc Sees FY2013 EPS $5.70-5.90 vs $5.67 Est; Sees Sales $805.0M-835.0M vs $811.30M Est,2013-02-26 16:08:00-05:00,JAZZ,neutral
693688.0,Jazz Pharmaceuticals plc Reports Q4 EPS of $1.53 vs $1.42 Est,2013-02-26 16:07:00-05:00,JAZZ,neutral
693689.0,Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook,2013-02-26 08:06:00-05:00,JAZZ,positive
693690.0,"Earnings Scheduled For February 26, 2013",2013-02-26 04:24:00-05:00,JAZZ,neutral
693691.0,Jazz Spikes Higher on Bank of America Initiation at Buy and $74 PT,2013-02-25 14:10:00-05:00,JAZZ,neutral
693692.0,"Bank of America Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces $74.00 PO",2013-02-25 14:10:00-05:00,JAZZ,negative
693693.0,"Jazz Pharma Issues Warning Against Using Xyrem with Alcohol, Drugs Which Cause Respiratory Depression",2012-12-17 10:41:00-05:00,JAZZ,negative
693694.0,Jazz Pharma Says FDA Denied July Citizens Petition Filed on Requirements for Xyrem ANDA; Co. Evaluating Further Actions,2012-12-13 17:34:00-05:00,JAZZ,negative
693695.0,Jazz Pharmaceuticals Presents Data from Safety Trial of Patients Treated with Erwinaze ,2012-12-10 19:24:00-05:00,JAZZ,positive
693696.0,Jazz Pharmaceuticals Announces Issuance of Additional Xyrem Patent,2012-12-04 16:07:00-05:00,JAZZ,neutral
693697.0,Jazz Pharma Reports Issuance of Added Xyrem Patent,2012-12-04 16:06:00-05:00,JAZZ,neutral
693698.0,Jazz Pharma Begins Trial of IV Administered Erwinaze,2012-12-03 16:05:00-05:00,JAZZ,neutral
693699.0,"UBS Initiates Coverage on Jazz Pharmaceuticals plc at Buy, Announces $64.00 PT",2012-11-29 12:02:00-05:00,JAZZ,neutral
693700.0,UPDATE: Citigroup Initiates Jazz Pharmaceuticals at Buy; Expecting Settlement to Remove Overhang  ,2012-11-27 13:57:00-05:00,JAZZ,neutral
693701.0,Benzinga's Top Initiations,2012-11-27 09:07:00-05:00,JAZZ,positive
693702.0,"Citigroup Initiates Coverage Jazz Pharmaceuticals at Buy, Announces PT of $70.00",2012-11-27 06:51:00-05:00,JAZZ,neutral
693703.0,"UPDATE: Jazz Pharma Guides FY EPS $4.65-4.75 vs $4.78 Est, sales $575-585M vs $611.1M Est",2012-11-08 16:50:00-05:00,JAZZ,neutral
693704.0,Jazz Pharmaceuticals Reports Q3 EPS $1.29 vs $1.32 Est; Revenues $176.0M vs $179.62M Est,2012-11-08 16:13:00-05:00,JAZZ,neutral
693705.0,Jazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda For $95M,2012-10-15 16:16:00-04:00,JAZZ,neutral
693706.0,"Barclays Maintains Jazz Pharmaceuticals at Overweight, Raises PT from $60 to $70",2012-10-12 12:57:00-04:00,JAZZ,negative
693707.0,"Brean Murray Carret Initiated Coverage on Jazz Pharmaceuticals at Buy, Announced PT to $81",2012-09-27 09:24:00-04:00,JAZZ,neutral
693708.0,"Guggenheim Initiates Coverage Jazz Pharmaceuticals at Buy, Announces PT of $60",2012-09-18 07:09:00-04:00,JAZZ,neutral
693709.0,"Jazz Pharma Says Ruling Generally Favorable to Its Positions, Received Markman Ruling September 17",2012-09-18 06:58:00-04:00,JAZZ,positive
693710.0,"Jazz Pharma Continues its Rally, Up 15.34%",2012-09-17 10:53:00-04:00,JAZZ,neutral
693711.0,"Jazz Pharma Rallies Up 11%, Markman Ruling Against Rozane Posted on Friday",2012-09-17 10:26:00-04:00,JAZZ,neutral
693712.0,"Jazz Pharmaceuticals Rises 8% on Patent News, Cowen Upgrade",2012-09-11 12:18:00-04:00,JAZZ,neutral
693713.0,Cowen Upgrades Jazz Pharmaceuticals to Outperform,2012-09-11 09:32:00-04:00,JAZZ,neutral
693714.0,Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem® ,2012-09-11 06:11:00-04:00,JAZZ,neutral
693715.0,Jazz Pharmaceuticals Sells Women's Health Business,2012-09-06 10:19:00-04:00,JAZZ,neutral
693716.0,A Peek Into The Market Before The Trading Starts,2012-09-06 07:14:00-04:00,JAZZ,neutral
693717.0,Jazz Pharmaceuticals Enters Definitive Agreement to Sell its Women's Health Business to Meda ,2012-09-06 06:07:00-04:00,JAZZ,positive
693718.0,Hearing Navellier Sell on Jazz Pharmacuticals,2012-09-04 13:06:00-04:00,JAZZ,neutral
693719.0,UPDATE: Piper Jaffray Raises PT on Jazz Pharmaceuticals from $64 to $68,2012-08-08 10:02:00-04:00,JAZZ,neutral
693720.0,"Piper Jaffray Maintains Jazz Pharmaceuticals at Overweight, Raises PT from $64 to $68",2012-08-08 06:35:00-04:00,JAZZ,negative
693721.0,Jazz Pharmaceuticals Reports Q2 EPS $1.09 vs $1.05 Est; Revenues $129.5 vs $125.53M Est,2012-08-07 16:11:00-04:00,JAZZ,neutral
693722.0,Jazz Pharmaceuticals Could See FDA Reinspection -FT,2012-06-19 12:08:00-04:00,JAZZ,neutral
693723.0,5 Healthcare Stocks With The Highest Operating Margin,2012-06-18 07:25:00-04:00,JAZZ,neutral
693724.0,"UPDATE: Credit Suisse Initiates Jazz Pharmaceuticals with Outperform, $65 PT; Organic and Acquisition Growth Outlook  ",2012-05-23 09:19:00-04:00,JAZZ,positive
693725.0,"Oppenheimer Initiates Coverage on Jazz Pharmaceuticals at Outperform, Announces PT of $66",2012-05-23 07:06:00-04:00,JAZZ,neutral
693726.0,Jazz Pharmaceuticals Down 4.5% on Weak 2012 Guidance ,2012-05-09 11:35:00-04:00,JAZZ,negative
693727.0,Jazz Pharmaceuticals Reports Q1 EPS $0.91 vs $0.84 Est; Revenues $108.4M vs $102.48M Est,2012-05-08 16:09:00-04:00,JAZZ,neutral
693728.0,Jazz Pharmaceuticals Rises 16% Pre-Market on EUSA Acquisitiion ($52.40),2012-04-27 09:25:00-04:00,JAZZ,neutral
693729.0,"Jefferies & Company Maintains Jazz Pharmaceuticals at Buy, Raises PT from $64 to $74",2012-04-27 07:07:00-04:00,JAZZ,neutral
693730.0,"Benzinga's M&A Chatter for Thursday April 26, 2012",2012-04-26 18:44:00-04:00,JAZZ,neutral
693731.0,Jazz Pharmaceuticals Rises 6% After-Hours on EUSA Acquistiion,2012-04-26 16:24:00-04:00,JAZZ,neutral
693732.0,Jazz Pharmaceuticals to Acquire EUSA Pharma for $650M; Transaction Would Be Immediately Accretive to Jazz Pharmaceuticals' Adjusted EPS,2012-04-26 16:15:00-04:00,JAZZ,neutral
693733.0,UPDATE: Citi Initiates Coverage on Jazz Pharmaceuticals,2012-04-10 08:24:00-04:00,JAZZ,neutral
693734.0,"Citigroup Initiates Coverage on Jazz Pharmaceuticals at Buy, Announces PT of $60",2012-04-10 06:14:00-04:00,JAZZ,neutral
693735.0,Longitude No Longer Holds More Than 5% Stake in Jazz,2012-03-14 17:27:00-04:00,JAZZ,negative
693736.0,"Jazz Pharma Says 7.88M Shares Being Sold by Holders, Company Will Not Receive Any Proceeds",2012-03-05 17:41:00-05:00,JAZZ,positive
693737.0,"Jefferies & Company Maintains Jazz Pharmaceuticals at Buy, Raises PT from $64 to $56",2012-03-01 06:57:00-05:00,JAZZ,neutral
693738.0,Jazz Pharmaceuticals Trading 2.8% Higher on Heavy Volume; Currently at $53.01,2012-02-29 14:00:00-05:00,JAZZ,neutral
693739.0,UPDATE: Auriga Raises PT to $57 on JAZZ Pharmaceuticals,2012-02-28 10:41:00-05:00,JAZZ,neutral
693740.0,UPDATE: Piper Jaffray Raises Jazz Pharmaceuticals PT,2012-02-28 09:49:00-05:00,JAZZ,neutral
693741.0,"Auriga Maintains Jazz Pharmaceuticals at Buy, Raises PT from $55 to $57",2012-02-28 06:42:00-05:00,JAZZ,neutral
693742.0,"Piper Jaffray Maintains Jazz Pharmaceuticals at Overweight, Raises PT from $61 to $64",2012-02-28 06:27:00-05:00,JAZZ,negative
693743.0,Jazz Pharmaceuticals Adds 2% on Q4 Earnings Results,2012-02-27 16:22:00-05:00,JAZZ,neutral
693744.0,Jazz Pharmaceuticals Reports Q4 EPS $1.17 vs $1.09 Est; Revenues $83.5M vs $80.84M Est,2012-02-27 16:08:00-05:00,JAZZ,neutral
693745.0,Jazz Pharmaceuticals Spikes Lower on Heavy Volume; Currently at $47.1,2012-02-17 15:11:00-05:00,JAZZ,negative
693746.0,Jazz Pharmaceuticals Hits 52-Week High of $51.02,2012-02-08 09:35:00-05:00,JAZZ,neutral
693747.0,Jazz Pharmaceuticals Hits 52-Week High of $50.47,2012-02-06 11:33:00-05:00,JAZZ,neutral
693748.0,Jazz Pharmaceuticals Trading 3.7% Higher on Heavy Volume; Currently at $49.77,2012-02-06 10:16:00-05:00,JAZZ,neutral
693749.0,Jazz Pharmaceuticals Trading 1.8% Higher on Heavy Volume; Currently at $48.87,2012-02-06 09:52:00-05:00,JAZZ,neutral
693750.0,Jazz Pharmaceuticals Trading 4.4% Higher on Heavy Volume; Currently at $48.54,2012-02-01 11:05:00-05:00,JAZZ,neutral
693751.0,KKR Discloses 24.6% Stake in  Jazz Pharma,2012-02-01 09:39:00-05:00,JAZZ,neutral
693752.0,Jazz Pharmaceuticals Spiking Lower,2012-01-30 10:27:00-05:00,JAZZ,negative
693753.0,Jazz Pharmaceuticals Spiking Higher on Heavy Volume,2012-01-27 10:30:00-05:00,JAZZ,neutral
693754.0,Jazz Pharmaceuticals plc Announces New Executive Appointments ,2012-01-24 16:41:00-05:00,JAZZ,neutral
693755.0,Jazz Pharmaceuticals Spiking Higher on Heavy Volume,2012-01-23 12:43:00-05:00,JAZZ,neutral
693756.0,Jazz Pharmaceuticals Resumes Trading,2012-01-18 08:50:00-05:00,JAZZ,neutral
693757.0,PREVIEW: Jazz Pharmaceuticals to Resume Trading at 8:50am,2012-01-18 08:35:00-05:00,JAZZ,neutral
693758.0,Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals ,2012-01-18 08:31:00-05:00,JAZZ,positive
693759.0,Hearing Chatter of Pfizer Buyout of Jazz Pharmaceuticals for $60/Share,2012-01-18 07:49:00-05:00,JAZZ,neutral
693760.0,Jazz Pharmaceuticals Halted; Pending News,2012-01-18 07:03:00-05:00,JAZZ,neutral
693761.0,Jazz Pharmaceuticals; Pending News,2012-01-18 07:02:00-05:00,JAZZ,neutral
693762.0,Jazz Pharma Sees 50% of Revenue to Drop Down to Adj Net,2012-01-11 13:35:00-05:00,JAZZ,negative
693763.0,Did John 3:16 Predict These Companies' Successes?,2012-01-09 13:40:00-05:00,JAZZ,positive
693764.0,Benzinga's Volume Gainers,2012-01-06 13:22:00-05:00,JAZZ,neutral
693765.0,Jazz Pharmaceuticals Rallying on Strong Outlook,2012-01-06 10:35:00-05:00,JAZZ,positive
693766.0,Jazz Pharmaceuticals Spiking Higher at the Open,2012-01-06 09:33:00-05:00,JAZZ,neutral
693767.0,Jazz Pharmaceuticals Sees FY 2012 Adjusted EPS of $4.00 – 4.15 vs $3.40 Est,2012-01-05 16:08:00-05:00,JAZZ,neutral
693768.0,"Jazz Pharma Says Will Update Azur Acquisition, Xyrem Drug Sales",2012-01-04 15:11:00-05:00,JAZZ,neutral
693769.0,ETF Showdown: Fun With Pharma,2011-12-30 16:10:00-05:00,JAZZ,positive
693770.0,Best Biotech Stocks of 2011,2011-12-27 10:39:00-05:00,JAZZ,positive
693771.0,Jazz Pharmaceuticals Announces Stockholder Vote in Favor of Transaction With Azur Pharma Limted ,2011-12-12 16:08:00-05:00,JAZZ,positive
693772.0,WBB Securites Downgrades Jazz Pharmaceuticals to Hold,2011-12-08 07:57:00-05:00,JAZZ,neutral
693773.0,Jazz Pharmaceuticals Spiking Lower on Heavy Volume,2011-11-04 12:36:00-04:00,JAZZ,negative
693774.0,"End-of-Day Market Summary for November 1, 2011",2011-11-01 16:14:00-04:00,JAZZ,neutral
693775.0,Jazz Pharmaceuticals Reports Q3 EPS $0.94 vs $0.94 Est; Revenues $73.3M vs $ 72.03M Est		,2011-11-01 16:03:00-04:00,JAZZ,neutral
693776.0,Jazz Reaffirms Xyrem Sales Forecast of $215-225M,2011-10-18 17:35:00-04:00,JAZZ,neutral
693777.0,"UPDATE: Piper Jaffray Defends Jazz Pharmaceuticals, Reiterates Overweight and $51 PT",2011-10-18 14:31:00-04:00,JAZZ,negative
693778.0,Piper Jaffray Defends Jazz Pharmaceuticals; Reiterates Overweight and $51 PT,2011-10-18 14:29:00-04:00,JAZZ,negative
693779.0,UPDATE: Jefferies Defending Jazz Pharmaceuticals,2011-10-18 13:31:00-04:00,JAZZ,neutral
693780.0,Jefferies Defending Jazz Pharmaceuticals ,2011-10-18 13:19:00-04:00,JAZZ,neutral
693781.0,Jazz Pharmaceuticals Spiking Lower,2011-10-18 09:40:00-04:00,JAZZ,negative
693782.0,Piper Jaffray Reiterates Overweight on Jazz Pharmaceuticals,2011-10-17 07:48:00-04:00,JAZZ,negative
693783.0,"Forest Laboratories Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",2011-10-13 23:02:00-04:00,JAZZ,negative
693784.0,Piper Jaffray Overweight on Jazz Pharmaceuticals ,2011-10-10 07:42:00-04:00,JAZZ,negative
693785.0,Piper Jaffray Reiterates Overweight on Jazz Pharmaceuticals,2011-09-26 07:48:00-04:00,JAZZ,negative
693786.0,Tuesday Afternoon Movers; Jazz Pharma Up 8%,2011-09-20 15:36:00-04:00,JAZZ,neutral
693787.0,Benzinga's Volume Movers,2011-09-20 10:13:00-04:00,JAZZ,neutral
693788.0,UPDATE: Jefferies Raises PT on Jazz Pharma to $56,2011-09-20 09:13:00-04:00,JAZZ,neutral
693789.0,Piper Jaffray Overweight on Jazz Pharmaceuticals,2011-09-20 07:58:00-04:00,JAZZ,negative
693790.0,Jefferies Raises PT on Jazz Pharmaceuticals to $52,2011-09-20 06:51:00-04:00,JAZZ,neutral
693791.0, Jazz Pharm Resumes Trading,2011-09-19 16:35:00-04:00,JAZZ,neutral
693792.0,PREVIEW: JAZZ Pharma to Resume Trading at 4:35 p.m.,2011-09-19 16:31:00-04:00,JAZZ,neutral
693793.0,Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals,2011-09-19 16:04:00-04:00,JAZZ,positive
693794.0,"Jazz Pharmaceuticals Halted, Pending News",2011-09-19 16:01:00-04:00,JAZZ,neutral
693795.0,Piper Jaffray: Jazz Pharmaceuticals Not Expecting Payer Pushback In Wake Of Price Hike,2011-09-01 09:58:00-04:00,JAZZ,neutral
693796.0,Afternoon Movers; Miners Gaining on Higher Gold Price,2011-08-30 15:55:00-04:00,JAZZ,positive
693797.0,Hearing Mid-Tier Firm Removed Jazz Pharma from its Buy List,2011-08-22 09:47:00-04:00,JAZZ,neutral
693798.0,Jazz Pharmaceuticals Positive Mention in Seeking Alpha Blog,2011-08-10 10:41:00-04:00,JAZZ,positive
693799.0,Jazz Pharma Spiking Higher on Heavy Volume,2011-08-10 10:34:00-04:00,JAZZ,neutral
693800.0,Stocks to Watch for Tuesday 8/02/2011: Fresh 52-Week Highs and Lows,2011-08-02 04:20:00-04:00,JAZZ,positive
693801.0,Benzinga's Volume Movers,2011-08-01 10:07:00-04:00,JAZZ,neutral
693802.0,"The Week Ahead, Morning Noteables August 1",2011-08-01 08:46:00-04:00,JAZZ,neutral
693803.0,"UPDATE: Jefferies Upgrades Jazz Pharmaceuticals To Buy, Raises PT To $52",2011-08-01 08:38:00-04:00,JAZZ,neutral
693804.0,"Jefferies Upgrades Jazz Pharmaceuticals To Buy, Raises PT To $52",2011-08-01 06:02:00-04:00,JAZZ,neutral
693805.0,Stocks to Watch for Monday 8/01/2011: Fresh 52 Week Highs and Lows,2011-07-31 22:55:00-04:00,JAZZ,positive
693806.0,Jazz Pharmaceuticals Soaring 15%,2011-07-29 15:12:00-04:00,JAZZ,neutral
693807.0,Jazz Pharmaceuticals up 14% on Upbeat Earnings ,2011-07-29 11:06:00-04:00,JAZZ,neutral
693808.0,Jazz Pharma Reports Q2 EPS $0.82 vs $0.77 Est; Revenues $64.6M vs $61.86M Est			,2011-07-28 16:05:00-04:00,JAZZ,neutral
693809.0,Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows,2011-07-20 01:51:00-04:00,JAZZ,positive
693810.0,"July 14th: Top Performing Small Cap Stocks (UFPI, BTH, UTEK, GLUU, JAZZ)",2011-07-15 10:38:00-04:00,JAZZ,positive
693811.0,Jazz Pharmaceuticals up Over 5% on Overweight Initiation,2011-07-14 11:35:00-04:00,JAZZ,negative
693812.0,"Piper Jaffray Initiates Jazz Pharmaceuticals At Overweight, $51 PT",2011-07-14 06:13:00-04:00,JAZZ,negative
693813.0,"Hearing Twitter Chatter on Jazz, Previously Locked Up Shares to be Sold Today",2011-07-07 07:17:00-04:00,JAZZ,positive
693814.0,Puts Purchased on Jazz Pharmaceuticals,2011-07-05 11:34:00-04:00,JAZZ,neutral
693815.0,Friday Stock Watchlist: 5 Technical Setups to Watch,2011-06-24 06:15:00-04:00,JAZZ,neutral
693816.0,Second Wave of Russell ETFs Comes Ashore,2011-06-01 18:29:00-04:00,JAZZ,neutral
693817.0,Flash Crash Could Still Happen (JAZZ),2011-05-04 17:41:00-04:00,JAZZ,negative
693818.0,Jazz Pharmaceuticals Hits 52-Week High (JAZZ),2011-04-14 10:56:00-04:00,JAZZ,neutral
693819.0,Jazz Pharmaceuticals Hits 52-Week High (JAZZ),2011-04-08 11:16:00-04:00,JAZZ,neutral
693820.0,"Options Brief: Jazz Pharmaceuticals, Inc. (JAZZ)",2011-03-18 13:54:00-04:00,JAZZ,neutral
693821.0,Buyers Step Back In  03-17-2011,2011-03-17 18:37:00-04:00,JAZZ,neutral
693822.0,Options Brief: Jazz Pharmaceuticals (JAZZ),2011-03-17 15:38:00-04:00,JAZZ,neutral
693823.0, Jazz Pharmaceuticals Reports EPS of $0.63 vs. $0.60; Revenues $53.4M vs. $51.05M,2011-03-07 16:03:00-05:00,JAZZ,neutral
693824.0,"Five Trade Ideas for Thursday, March 03",2011-03-02 18:48:00-05:00,JAZZ,neutral
693825.0,Jazz Pharmaceuticals Jumps 8% To New 52-Week High (JAZZ),2011-01-10 13:18:00-05:00,JAZZ,neutral
693826.0,Jazz Pharmaceuticals Up 8% After Hitting 52-Week High (JAZZ),2011-01-10 13:18:00-05:00,JAZZ,neutral
693827.0,Calls Purchased on Jazz Pharmaceuticals (JAZZ),2011-01-06 15:51:00-05:00,JAZZ,neutral
693828.0,Calls Purchased on Jazz Pharmaceuticals (JAZZ),2010-12-20 14:24:00-05:00,JAZZ,neutral
693829.0,Puts Purchased on Jazz Pharmaceuticals (JAZZ),2010-12-13 13:48:00-05:00,JAZZ,neutral
693830.0,New Analyst Coverage - Screen of the Week,2010-12-07 13:33:00-05:00,JAZZ,neutral
693831.0,New Analyst Coverage - Screen of the Week,2010-12-07 00:00:00-05:00,JAZZ,neutral
693832.0,"Unconfirmed Rumors continue to swirl that Jazz Pharmaceuticals, Inc. (JAZZ) is a takeover target by (CEPH) at $22.00 a share",2010-11-18 10:33:00-05:00,JAZZ,positive
693833.0,"NASDAQ Biotech/Pharma Stock Watch ; (NASDAQ:BPAX), (NASDAQ:MNKD), (NASDAQ:SPPI)",2010-11-12 13:13:00-05:00,JAZZ,neutral
693834.0,"Unconfirmed Rumors that Jazz Pharmaceuticals, Inc. (JAZZ) is a possible takeover target in the mid $20s possible suitors include Cephalon Inc. (CEPH) and (PFE)",2010-11-12 11:32:00-05:00,JAZZ,negative
693835.0,"Mad Money Lightning Round: Cramer Likes Honeywell (HON, JAZZ, ICLR, ANDE, DE, TSCO, STD, FCS, BIDU, GOOG, NAT)",2010-11-09 03:36:00-05:00,JAZZ,negative
693836.0,"NASDAQ Stocks Hitting 52-Week Highs (CCME, JAZZ, RURL, AERL)",2010-11-08 10:41:00-05:00,JAZZ,neutral
693837.0,Jazz Pharmaceuticals Hits 52-Week High (JAZZ),2010-11-05 10:59:00-04:00,JAZZ,neutral
693838.0,Jazz Pharmaceuticals Grooves Higher (JAZZ),2010-11-05 09:57:00-04:00,JAZZ,neutral
693839.0,"Benzinga's After Hours Gainers (WRLS, JAZZ, IGOI)",2010-11-04 18:41:00-04:00,JAZZ,neutral
693840.0,Jazz Pharmaceuticals Soars 12% After Hours (JAZZ),2010-11-04 17:43:00-04:00,JAZZ,neutral
693841.0,Jazz Pharmaceuticals Announces Q3 EPS of $.41,2010-11-04 16:31:00-04:00,JAZZ,neutral
693842.0,Jazz Pharma Downgraded to Buy,2010-11-03 10:38:00-04:00,JAZZ,neutral
693843.0,Jefferies Downgrades Jazz Pharma to Hold (JAZZ),2010-10-12 09:51:00-04:00,JAZZ,neutral
693844.0,"Benzinga's Top Downgrades (ALXA, CEO, NBHGY, JAZZ)",2010-10-12 06:33:00-04:00,JAZZ,positive
693845.0,"Benzinga's Top Pre-Market NASDAQ Losers (JAZZ, ACGY, ARMH, RIMM)",2010-10-11 09:02:00-04:00,JAZZ,negative
693846.0,Jazz Pharmaceuticals Receives FDA Response Regarding its Treatment of Fibromyalgia,2010-10-11 07:58:00-04:00,JAZZ,neutral
693847.0,Protection Purchased on Jazz Pharmaceuticals (JAZZ),2010-10-08 12:18:00-04:00,JAZZ,neutral
693848.0,What's Hot On TheStreet,2010-09-03 13:19:00-04:00,JAZZ,neutral
693849.0,"Tech Stocks Fly, Pharma Stocks Cry! (DELL, HPQ, PAR, CML, CVLT, ISLN, TPL, JAZZ, EPCT, CPIX)",2010-08-23 13:11:00-04:00,JAZZ,negative
693850.0,"Benzinga’s Top Pre-Market NASDAQ Losers (JAZZ, SAFM, PDLI, COCO)",2010-08-23 08:50:00-04:00,JAZZ,negative
693851.0,Sector Leaders  08-18-2010,2010-08-18 14:49:00-04:00,JAZZ,neutral
693852.0,"Benzinga’s Volume Movers (JAZZ, ENDP, CAGC, STRA)",2010-08-18 12:31:00-04:00,JAZZ,neutral
693853.0,Jazz Pharmaceuticals Rising After Positive FDA Commentary (JAZZ),2010-08-18 10:34:00-04:00,JAZZ,positive
693854.0,"Benzinga’s Top Pre-Market NASDAQ Gainers (CRDC, PTEC, JAZZ, JDSU)",2010-08-18 08:33:00-04:00,JAZZ,positive
693855.0,"Benzinga’s Top Pre-Market NASDAQ Gainers (SYUT, EGL, JAZZ, ITMN)",2010-08-16 08:28:00-04:00,JAZZ,positive
693856.0,Jefferies Has Some Thoughts On Jazz (JAZZ),2010-08-13 10:48:00-04:00,JAZZ,neutral
693857.0,"Benzinga’s Volume Movers (ASCA, JAZZ, HMIN, MATK)",2010-08-11 14:10:00-04:00,JAZZ,neutral
693858.0,"Jazz Pharmaceuticals Reports Strong Quarter, Ups Guidance (JAZZ)",2010-08-10 16:50:00-04:00,JAZZ,positive
693859.0,"Benzinga’s Top Pre-Market Gainers (FCEL, NLST, JAZZ, HERO)",2010-06-15 08:43:00-04:00,JAZZ,positive
693860.0,"Benzinga’s Top Upgrades (CELG, YSI, JAZZ, TRW)",2010-06-15 07:08:00-04:00,JAZZ,positive
693861.0,Barclays Upgrades JAZZ To Overweight,2010-06-15 06:42:00-04:00,JAZZ,negative
693862.0,Jazz Pharmaceuticals To Raise $58.5M In Secondary Offering,2010-05-11 13:03:00-04:00,JAZZ,neutral
693863.0,"Benzinga’s Volume Movers (PLCM, ABII, SMTS, JAZZ, RBCN)",2010-03-17 14:21:00-04:00,JAZZ,neutral
693864.0,"Jim Cramer Comments On IVR, CPL, JAZZ",2010-03-02 19:26:00-05:00,JAZZ,neutral
693865.0,"Benzinga’s Top Pre-Market Losers (CAT, ZAGG, INSP, JAZZ, FSIN, HERO)",2010-01-27 08:29:00-05:00,JAZZ,negative
693866.0,"Benzinga’s Volume Movers (CREE, RMBS, CETV, JAZZ, ASYS)",2010-01-20 14:50:00-05:00,JAZZ,neutral
693867.0,"NASDAQ's Most Advanced Today (LIMS, ARRY, SGEN, JASO, JAZZ)",2009-12-15 13:43:00-05:00,JAZZ,positive
693868.0,"Benzinga’s Top Pre- Market Gainers (LIMS, SGEN, CLNE, ARRY, JASO, JAZZ, SPWRA)",2009-12-15 08:39:00-05:00,JAZZ,positive
693869.0,"TheFortuneFinancial.com Free Market Research on CVBF, ESRX, CTAS, FUQI, JAZZ and GILD",2009-08-17 06:40:00-04:00,JAZZ,positive
